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Hypothesis
Man-made ponds and the Atchafalaya Basin are crayfish habitats that may be influenced
by heavy metal contamination from pesticides, insecticides, herbicides, fungicides, and
fertilizers. Research suggests that certain products laden with arsenic and cadmium are
carcinogens. The research herein is designed to identify, quantify, and compare heavy metal
contamination of ingested arsenic, cadmium, copper, and zinc concentrations in crayfish tails and
intestines consumed by humans in specific south Louisiana locales. The locales tested were
chosen to reflect the heart of the crayfish industry, and had not previously been tested for heavy
metal contamination.
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Abstract
Heavy metal contamination in food is a worldwide concern. Man-made ponds are
domestic sites in the production of Procambarus clarkii and Procambarus zonangulus, two edible
species of crayfish. Ponds may be constructed in former sugar cane or rice fields. Crayfish
farming is an ancillary seasonal business within the rice-growing season. The use of products to
control insects, pests, and weeds in rice and sugar cane production, may cause an accumulation
of heavy metals in the crayfish tail within pond structures. Arsenic, cadmium, copper, and zinc
are heavy metals that are absorbed through the roots of and distributed through rice products.
Metabolites associated with rice products are absorbed in the human body. Research suggests
that metabolites associated with heavy metals cause disease in animals and humans.

Keywords: Methylation, Metabolites, Mean, Pesticides, Fertilizer
viii

Chapter 1 – Introduction
Arsenic poisoning is the greatest single cause of ill health in the world today (WHO,
2012). The Environmental Protection Agency (EPA) states that arsenic is a naturally occurring
element in soil and water and may be a source for absorption of arsenic by plants. There are no
federal regulations limiting soil arsenic levels in the US. The EPA superfund risk model gives a
value of 0.43 ppm total soil ingestion exposure of arsenic for a cancer risk of 1 in 106 (Duxbury
and Zavala, 2012). Arsenic from hydrothermal veins and igneous rock bodies are associated with
cobaltite, arsenopyrite, and arsenic products. Erosion from land use and smelting plants are
sources of arsenic. Mineral processing and various domestic products such as paint and
preservatives are also sources of contamination. Groundwater associated with geothermal
activity is sometimes arsenic-rich (Rahman, et al., 2012).
The average level of arsenic is 5 ppm in U.S. soils, whereas in other countries it can vary
from 10-20 ppm from agricultural use. Arsenic is the twentieth most common element in the
earth’s crust, entering the environment usually by volcanic or industrial activities. Arsenic is also
present in 200 known mineral species. Mean air concentrations of arsenic are in the 0.02-4 ng/m3
in remote areas and from 3-200 ng/m3 in urban areas. Background or mean soil levels of arsenic
can range from 1 – 5 mg/kg to a high of 40 mg/kg. Foods usually contain less than 0.25 mg/kg,
depending on anthropogenic and pesticide usages in the tested soils (World Health Organization,
2001). Arsenic will adsorb to particulate matter and sediment, existing as arsenic As5+ and As3+
in two oxidation states. Arsenic sulfide (As2S3) exists in the oxidizing state and Arsine (ASH3)
under reducing conditions. According to the Agency for Toxic Substances and Disease Registry
(ATSDR), airborne arsenic particulate matter is oxidized by microbial action to nonvolatile
species, and settles back to the ground (2006).
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Toxicity occurs with a series of reactions that result in the reduction of inorganic
Arsenate (As5) to Arsenite (As3), methylation to Monomethylarsonic acid (MMAV), reduction to
Monomethylarsonous acid (MMA3), and methylation to Dimethylarsinic Acid (DMA5). Arsenic
is recognized as one of the most global toxicants, causing acute and chronic health effects
inclusive of cancer. Arsenic is an analog of phosphates and can replace phosphates in many
critical cellular functions, producing cellular toxicity or mutagenicity. Bio-accumulation is
inevitable in humans and animals. (ATSDR, 2007)
Arsenic undergoes reactions in the environment including oxidation-reactions,
precipitation, bio-transformation and ligand exchanges. Conditions are influenced by Eh (the
oxidation-reduction potential), pH, metal sulfide, sulfide ion concentrations, iron concentrations,
temperature, salinity, and distribution and composition of the biota (ATSDR, 2007).
Mining or manufacturing areas have higher arsenic concentrations. The standard level of
arsenic in drinking water adopted by the EPA on January 23, 2006 is 10 µg/L, replacing the
previous level of 50 µg/L. Arsenic occurs naturally in coal and oil, thus arsenic is released into
the atmosphere as a result of coal and oil-fired power plants. Cotton ginning is a source of
arsenic emissions released to the atmosphere, when cottonseeds are removed from raw cotton.
U.S. emissions to the atmosphere were estimated to be 3,300 metric tons per year between 1979
and 1986 (ATSDR, 2007). Industrial regulations of coal burning plants have reduced arsenic
emissions since the 1980s. At one time, copper smelting and coal combustion accounted for 65%
of anthropogenic emissions, approximated to be about 12,000-25,000 metric tons a year with
natural sources depositing about 11,000 – 23,500 tons per year (ATSDR, 2006).
Processing plants and factories create abundant commercial run offs, and arsenic
exposure in rivers, lakes, streams, and ponds adversely affecting ground water. Pesticides and
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fertilizers also release arsenic to the soil. Roxarsone, a drug added to poultry feed to improve
production, also contains organic arsenic (ATSDR, 2006).
The iron content of the soil affects arsenic absorption. Arsenic absorbed by iron and
manganese is released and reduced especially during flooding conditions. Abundant nutrients
available for microbial action may result in dissolution. Soil drying after flooding increases
arsenic action through mineralogy or iron absorption (ATSDR, 2007).
The oxidation states of arsenic exist as As5+, As3+, arsenic (Aso), and ASH3. Generally, the
inorganic species is more toxic than the organic, depending on concentration and speciation.
As3+ is more toxic than As5+, whereas dimethylarsinous acid (DMAIII) and monomethylarsonous
acid (MMAIII) are more toxic as metabolites than the parent compounds of As3+. The best
metabolite concentration indicator is an arsenic urine sample test. Monomethylarsonic acid
(MMA (V)) and dimethylarsinic acid (DMA(V)) -- both indicators of recent exposures -- are
often misidentified. Recent studies revealed monomethylmonothioarsonic acid (MMMTAV) and
dimethylmonothioarsinic acid (DMMTAV) in red blood cells and possibly in other cells, pose 10fold less toxicity than MMAIII and DMAIII. These metabolites are associated with sulfurcontaining methylated inorganic exposures. When testing urine samples for arsenic exposure,
they are often misidentified as MMAIII and DMAIII in exposed individuals, sometimes
confounding results, although considered deleterious to human health as carcinogens and cancer
causing substances (Van de Wilde et al., 2010).
Inorganic arsenic is most abundant in several countries; Argentina, Chile, India (West
Bengal), Mexico, and the United States of America as well as Bangladesh, with half of the total
population at risk with the extremely high arsenic contamination in the drinking water supply in

3

tube wells. One estimate from these locales showed 9100 deaths and 125,000 disability-adjusted
life years due to arsenic exposure (Duxbury & Zavala, 2012).
Smoking cigarettes introduces pesticide-laden tobacco into the human body. Lung cancer
is directly associated with cigarette smoking. Arsenic is methylated and eliminated from the
body by the urinary process. The methylation process is inhibited by lowering arsenic
elimination from the human body. Smoking acts synergistically with arsenic exposure causing
DNA damage in the lungs. Smokers have a higher risk of lung, bladder, and skin lesions
associated with cancer as well as heart disease (Lazarevic et al., 2012).
The World Health Organization’s arsenic guidelines established the tolerable intake level
of arsenic in 2010. The scientific evidence by the Joint Food and Agriculture Organization of the
United Nations (FAO) and the WHO also determined the lower limit benchmark dose of arsenic
from epidemiological data to be 3.0 µg/kg body weight per day and 2-7 µg/kg body weight per
day, based on the range of estimated total dietary exposure. Ingesting levels below the lower
benchmark reduces the incidence of lung cancer below the minimum detectable limit (BMDL
0.5). The previous provisional tolerable weekly intake (PTWI) of 15 µg/kg body weight BMDL
0.5 (equivalent to 2.1 µg/kg body weight per day) for inorganic arsenic is no longer appropriate,
and the benchmark was withdrawn. The WHO tolerable limits of drinking water and arsenic
levels are acceptable; no new tolerable guidelines have been established. Ten µg/L or below is
the acceptable WHO guideline for arsenic in drinking water (Duxbury and Zavala, 2012).
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Chapter 1.1 – Procambarus clarkii and Procambarus zonangulus
This study tested accumulation of arsenic in Procambarus clarkii (Red Swamp crayfish)
and Procambarus zonangulus (White River crayfish) in crayfish ponds converted from rice
(Oryza sativa) and sugarcane fields in central and southwest Louisiana, and in the Atchafalaya
Basin (Anderson et al., 1997).
Crayfish farming incorporates the use of fertilizers, pesticides, herbicides, and
fungicides creating a possible accumulative effect of arsenic in the particular pond from which
the sample of crayfish species were procured. Arsenic is taken up in the rice shoots grown in
the particular pond for food. Afterwards, research suggests the crayfish ingest the rice
containing arsenic as food, and are then consumed by humans (Avery and Lorio, 1999).
Arsenic is methylated and bio-transformed in marine and fresh waters, creating toxic
metabolites. Research suggests that some forms of arsenic metabolites like arsenobetaine (AsB)
are innocuous, due to a covalent bond that prevents toxic metabolite formation. It is a form of
organic arsenic found in seafood that is excreted in the urine (Devesa et al., 2005). However,
there are reports that show at very high concentrations some arsenobetaine will be metabolized in
humans (Choi, 2010).
Farmed crayfish in converted ponds may be susceptible to inorganic arsenic
contamination and accumulation from fertilizers, insecticides, pesticides, herbicides, and
fungicides. Previous contamination from sugarcane, corn, or rice field crops over the years may
have an impact on arsenic contamination and accumulation in the ponds. Humans consume
crayfish; thus, arsenic will bio-accumulate. Some arsenic metabolites are known cancer-causing
substances. The research design attempts to quantify arsenic content in pond-raised crayfish, as
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compared to wild-grown crayfish, possibly determining a higher Minimum Risk Level (MRL)
contamination in humans (Avery and Lorio, 1999).
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Chapter 1.2 – History of Growing Crayfish
A commercial source of seafood in Louisiana, crayfish date back to the 1800s to the old
French market of New Orleans. In 1940 a commercial fishery for wild crayfish harvested in the
Atchafalaya swamp, and to this day provides a large catch each year. The 1950s showed an
experimental industry with new pond acreage continually increasing with time. Crayfish ponds
vary widely in shape and size. Ponds are normally 10-20 acres, with larger producers managing
up to100 acres. Louisiana is the largest producer of crayfish in the US. Crayfish are not formulafed, but instead are allowed to ingest rice, sorghum-sun grass, or other natural vegetation.
Farmers rely on un-harvested crayfish for the next year’s brood stock (Avery & Lorio, 1999).
Varying production yields affect profits from year to year. Consultation from local higher
education entities, such as LSU Co-Operative Extension aids in decision-making relative to
crayfish farming and its success (Avery and Lorio, 1999).
Thirty-two species of crayfish have been identified in Louisiana. The two most important
economic species are the Red Swamp and White River crayfish. Both can be grown in the same
pond, although the Red swamp crayfish makes up approximately 80% of the annual catch. Adult
Red Swamp crayfish are distinguished from the White River species. The Red Swamp crayfish
has two halves of the carapace meeting to form a thin line. White River crayfish exhibit a
separation between the two halves of the carapace and lighter colored walking legs. Red swamp
crayfish have a vein line on the underside of the tail. The White River crayfish does not have a
vein line (Avery and Lorio, 1999).
After mature crayfish mate, the female burrows deep into the levee from 4-6 inches
above the water level. After an ovarian development period of 2-5 months, anywhere from 100
to 700 eggs are deposited and attached to swimmerets on the underside of their bellies. Eggs
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usually hatch in 2 – 3 weeks under ideal conditions, but may take 3 – 4 months in winter. Red
Swamp crayfish reproduce up to twice as often as White River crayfish (Avery and Lorio, 1999).
Crayfish production peaks in the spring weather during April through June. Crayfish
burrow deep into the ground during dry months seeking moisture, and returning to the surface
primarily during the fall, when the rainy season begins. Crayfish may be found 6-8 feet deep
below the earth's surface in some cases. Wetlands and surface locations fill up with water during
the rainy season beginning in autumn, and the crayfish return to the surface, depositing their eggs
and offspring in open water, setting the stage for the new season's harvest. Availability of
crayfish depends on weather and rain, creating a new cycle of production (Avery and Lorio,
1999).
The Atchafalaya Basin, a long time haven, provides the natural habitat for wild crayfish
production. A short season prevails in the wild every year, although a catch is eminent under
normal weather conditions. The Atchafalaya Basin is the cradle of the crayfish industry, dating
as far back as early Native Americans, who introduced the European settlers to the crayfish, a
delicacy as well as a food source for survival (Avery and Lorio, 1999).
In the late 1960s, LSU and A & M College started assisting aquaculture with crayfish
farming, and still provide the foundation and structure of crayfish farming today. Some farmers
rotate the rice and crayfish crops from year to year, although most farmers leave the rice in the
fields as leftover for the crayfish. The full term of crayfish from hatching to consumption is 90
days (Avery and Lorio, 1999).
Crayfish, like crabs and lobsters, occasionally lose their hard shell, and can double in size
every time they molt. October flooding summons female crayfish to resurface and to deposit
their eggs. Early spring is the greatest period of consumption (Avery and Lorio, 1999).
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Barometric pressure activates the production of crayfish during rainy periods. The pond crayfish
season starts in November in a warm year, and as late as February in a cold year, lasting as late
as July (Avery and Lorio, 1999).
Studies associated with heavy metals performed in the past reveal information relative to
arsenic contamination in areas of natural habitats of crayfish. Abdominal muscles and
hepatopancreatic tissue were analyzed separately for lead, mercury, and cadmium, whereas
arsenic was discovered in defoliating agents from the use of arsenicals (now banned) in
pesticides. Tests showed as much as 380 mg/kg of arsenic due to contamination by metal
processing in industry, and 625 mg/kg of arsenic from arsenical pesticides (Finerty et al., 1990).
Accumulation of arsenic occurs in the gills, exoskeleton, hepatopancreatic viscera, and
abdominal muscles. Concentrations of heavy metals in crayfish organs were highest in the gills
and hepatopancreas, which serve as biomarkers of pollution (Anderson et al., 1997; Tunca et al.,
2013). Note that in a particular analysis of male and female crayfish, the female showed less
bioaccumulation of nickel and arsenic in gill tissues, as compared to males in the same species.
The gills and the exoskeleton had the highest concentration of heavy metals (Tunca et al., 2013).
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Chapter 1.3 – Sugar Cane
Louisiana produces 42% of the sugar cane produced in the US. In the 1720s, the French
brought sugarcane plants to Louisiana. After initial failed attempts to produce sugar, commercial
scale production of sugar cane began in 1796 with 100,000 pounds. In 1891, Louisiana
production was 550 million pounds of sugar. (Gianessi, 2009)Approximately 455,000 acres
yields about 21 billion pounds of sugar valued at $260 million dollars per year. Louisiana sugar
mills produce 2.8 billion lbs of raw sugar annually (Gianessi, 2009).
The sugarcane borer is the most damaging insect to the sugarcane industry. Only 10% of
the pests survive the winter, hibernating in scraps of cane, grass, cane stubble, and planted cane.
Natural mortality factors controlling the borer population are cold weather and rain. The larvae
eggs hatch in spring and immediately begin foraging for survival. A 1925 severe infestation of
the borers destroyed one-third of the total crop in the state. Parasites were introduced to control
the borer population as done in the Caribbean Islands. Most of the parasites died off, and only
one species was left to control about 4% of the borer population from year to year (Gianessi,
2009).
Arsenals were first used in the control of borers, but were not effective. The larvae would
push the arsenals to the side before feeding, and less than 20% were destroyed. Research created
genetic changes on the leaf-sheath as well as the cane stalk that prevented larval movement, and
hardened of the internodes, reducing penetration of the canestalk and feeding of the borer. The
inorganic compound cryolite, a naturally occurring mineral, was introduced into the cane fields
in the early 1920s for borer control. Fire ants were also introduced as a predator to the borer in
sugarcane fields, but the fire ant populations later had to be controlled using heptachlor.
Heptachlor was replaced several times, first with endrin, an organochlorine, then with azinphos-
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methyl, an organophosphate in 1964 (Gianessi, 2009). Botanical compounds of Ryania, a
mixture of alkaloids made from a plant root, were replaced with synthetic organic chemicals,
improving the sugarcane borer control program in Louisiana. Applications were reduced from 12
to 2 due with the introduction of tebufenozide, a much more effective insecticide (Gianessi,
2009).
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Chapter 1.4 – Background Research
The research herein on tails and intestines is being compared to previous research on
arsenic associated with crayfish from petroleum-based effluents deposited in a Louisiana
waterway by a manufacturing plant. Arsenic, lead, chromium, and copper were found, although
arsenic and cadmium were lower in content. The hepatopancreas and gills showed significant
accumulation whereas copper was identified but did not show any significant change during the
research study. Abdominal muscles showed little accumulation of arsenic, due to a lower
percentage in the sediment tested as a primary factor in the wetland research. This research
paralleled sediment concentrations according to test results in the wetlands study with the
pollution of hydrocarbons containing heavy metal concentrations (Anderson et al., 1997).
Heavy metalloid research was conducted on the exoskeleton, gills, hepatopancreas, and
abdominal muscle tissues of the Astacus leptodacylus specimen at a wetland site in Turkey.
Eleven metals were tested including aluminum, chromium, manganese, cobalt, nickel, copper,
molybdenum, silver, cadmium, mercury, lead, and arsenic. Correlation trends were established
and evaluated by Inductively Coupled Plasma-Mass Spectrometry (ICP-MS). Elements were
evaluated in tissue samples of both heavy metal and metalloid concentrations (Tunca et al.,
2013).
An assessment of the human health risk associated with consuming the herbicide, 2,4dichlorophenoxyacetic acid and monosodium methanearsonate was performed. The exposed
crayfish showed an exposure dose at the high end of consumption that was approximately twice
the reference dose for arsenic. The cancer risk averaged approximately 7 extra tumors in a
population of 10,000. Six extra tumors in a population of 10,000 resulted from a lifetime
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consumption of crayfish, exposed to the herbicide mixture with or without surfactant. (Green and
Abdelghani, 2004)
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Chapter 2 – Arsenic
The EPA states that arsenic is a naturally-occurring element in soil and water. The EPA
also assumes there is no safe level of exposure to inorganic arsenic. Rice seems to be the biggest
provider of arsenic in the organic form. Limiting intake of rice products is a good defense against
arsenic. Testing showed that total inorganic arsenic levels were always higher for brown rice
than white rice (Snyder & Slaton, 2001). Research suggests that cancer is prevalent in south
Louisiana, and suggests a correlation between cancer rates and the consumption of cereal and
rice products (66% through consumption of plant sources, and 33% from animal sources)
(Luckett et al., 2012).
Sixty-five rice products have been analyzed and ranked categorically as 100 substances
that are Group 1 carcinogens. Arsenic is known to cause bladder, kidney, and prostate cancer in
humans. The US is the leads agriculture and industry with 1.6 million tons of arsenic used since
1901. Lead arsenate insecticides caused bioaccumulation in soil and water, although banned in
1980. Fertilizers made from poultry waste may contaminate crops with inorganic arsenic.
(Bellows, 2005)
Research suggests deleterious effects from arsenic exposure established by The Food and
Drug Administration (FDA) with a limit of .01 mg/L, in the US as the acceptable limit in
drinking water. Disease and effects are more profound in areas of unregulated drinking water
supplies. Use in paints and wood preservatives is common in home construction and industry,
creating a potential dust particle inhalation factor from degradation of wood products during
construction, remodeling, and demolition. Arsenic ingestion from water supplies, inhalation of
dust particles, and food supply contamination are the primary means of disease contraction in
humans and animals. Education and mechanical remediation can lesson potential contamination.
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In-home water filtering systems can remove the toxic element from drinking water. Proper
handling of food supplies can reduce the intake of arsenic as well. Problems with arsenic are
becoming less common worldwide because of improved precautions (Consumer Reports, 2012).
Arsenic was used as a chemotherapeutic in the treatment of infectious diseases such as
syphilis and typanosomiasis. The therapeutic attributes are far outweighed by its toxic effects
with higher doses and accumulation due to food and water intake (Kaur et al., 2011; Lundh et al.,
2010).
Aquatic environments are the recipients of household and industrial discharges with
arsenic, as well as spraying pesticides on gardens and farmlands. Aquatic pollution adds to the
concentration and bioaccumulation of plant absorption as well as accumulation of the metalloid
in fish in polluted waters, which are both eaten by humans. Disposal strategies and discharges
are sometimes deleterious to the environment, increasing the arsenic levels in ground water
supplies. Birds that eat fish with high concentrations of arsenic will die from the fish
decomposition containing high concentrations of arsenic in their bodies (Kaur et al., 2011;
ATSDR, 2007).
Arsenic is a known neurotoxin with natural body mechanisms aiding in the excretion and
extraction of the substance. Urinal, stool, and breath extraction methods aid in the discharge of
arsenic. Excessive intake lodges in tissues, inhibiting cellular activities. Not only interfering with
homeostasis, arsenic intensifies the onset of lung, liver, and lymphatic cancers in the human
body. Higher concentrations cause infertility and miscarriages in women, infection resistance,
and brain damage in both men and women. The National Toxicology Program considers arsenic
DNA damage a human carcinogen. The allowable MRL associated with arsenic is 10-50 ppb as
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stated by the EPA. The MRL for oral acute ingestion is .005 mg/kg/day and .0003 mg/kg/day for
chronic ingestion (Kaur et al., 2011; Lundh et al., 2010).
Transplacental arsenic exposure caused an increase in estrogen receptor-a (ER-a)
transcript and protein levels in the lungs of females. Arsenic exposure also caused an insulin
growth factor (IGF), an Estrogen Receptor (ER) catalytic response, and pulmonary oncogenic
process activation in the fetal lung. The data set and research shows evidence of arsenic-induced
aberrant ER signaling in early life stages and genetic programming, causing tumors in the lung
later in adulthood (Shen et al., 2007).
DMAV, a metabolite of ingested inorganic arsenic is associated with urinary bladder
cancer in rats and a multi-tumor promoter in mice and rats. Research shows that lung adenomacarcinomas increased from 0 % to 20% in C3H mice with gestational inorganic arsenic inducing
pulmonary carcinogenesis promoted by phorbol esters (croton oil) in male and female offspring.
It acts synergistically as a tumor promoter. Succinct evidence of trans-placental factors indicative
of arsenic crossing the rodent and human placenta, acting on fetal development, shows the lung
as a target of arsenic carcinogenesis (Shen et al., 2007).
Many parts of the world less regulated by government agencies, such as the FDA in the
US, must address contamination levels as causations of bladder, skin, and lung perturbations.
Research suggests that individuals subjected to levels of 300 ppb have a 1 in 300 chance of a
cancer diagnosis. Amazingly, one can ingest that much organic arsenic in a half-cup of rice or a
glass of fruit juice, much higher than the MRLs as compared to a glass of pure drinking water
(Lundh et al., 2010). According to some research mediums, the food industry denies the presence
of organic arsenic forms found in rice or fruit juices (Lundh et al., 2010).
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Arsenic-based pesticides are often used in the rice growing process. The bioaccumulation
of the generated rice product is arsenic laden with levels that abnormally affect homeostasis,
possibly creating carcinogenic effects. The FDA is presently testing arsenic levels with statistical
and concise analysis. The demand is a pronounced statistical approach to determine arsenic
levels in consumable rice products and minimizing risks associated with intake. Acceptable
naturally occurring arsenic levels or the Maximum Contaminant Level (MCL) is 0.01 mg/L. This
level is considered safe for drinking water for long-term consumption, which is the actual
Department of Health guideline for private water wells. Risk assessments monitor both organic
and inorganic forms of arsenic testing mediums that do not usually differentiate between the two
in reporting a concentration level, although inorganic arsenic is considered more deleterious to
human health. A major source of ingested arsenic is a fish diet, providing a larger intake of the
organic source or arsenobetaine. Some research suggests that arsenobetaine is much less
dangerous as a cancer causing substance (Cubadda et al., 2012).
Higher exposures to inorganic arsenic in individuals living in high-risk areas are of
concern. Instead of inorganic arsenic testing, metabolite analysis in urine is more reliable for
determining exposure using speciation analysis. Metabolites are a better indicator of food and
water arsenic contamination in people chronically exposed to the heavy metal.
Dimethylarsinic acid (DMA) and monomethylarsonic acid (MMA) are ingested as arsenic and
discharged as metabolites. Methylation capacity is measured by MMA and DMA proportions
unless food rich in DMA or those that contain arsenic compounds are metabolized to DMA that
would confound the results (Cubadda et al., 2012).
Inorganic arsenic is known as a human carcinogen and can produce cardiovascular
disease as well as diabetes. Fetal and infant development is also impaired depending on
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individual variations relative to arsenic metabolism. Cereal and grain foods for dietary intake
may also be sources of arsenic, when not subjected to aquatic exposure. Rice and algae foods are
known to have a higher content of arsenic well above the normal daily intake level (Roman et al.,
2010).
As stated previously, intake of inorganic arsenic is most important with urinary arsenic
testing and observance. Results are less substantial unless DMA and MMA are the realized
measures associated with physiological arsenic discovery (Cubadda et al., 2012).
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Chapter 2.1 – Arsenic Contamination in Other Countries
Arsenic contamination exceeding threshold limits can inhibit and harm homeostasis.
Cardiologic studies or non-cancer effects show that high levels of arsenic over the allowable
level of 50 µg/L in drinking water may also cause cancer (Kaur et al., 2011).
Bangladesh, Chile, and the West Bengal region of India have a pervasive problem with
organic earthen arsenic being released into drinking water supplies, causing bioaccumulation and
its resultant effects in pregnant mothers. Incidences of chronic cough, bronchitis, shortness of
breath, and obstructive or restrictive lung disease are clinical conditions produced by arsenic,
both carcinogenic and non-carcinogenic. Rat embryos exposed to arsenic up to day 18 of
gestation with 500 ppm altered gene expression in 59 genes and 34 proteins, and altered the Bcatinin and c-myc pathways (regulators of lung development that play a role in lung cancer and
chronic lung diseases) (Petrick et al., 2009).
Machinery mechanisms are the answer in Bangladesh, as new technology is developed
that will facilitate removal of the element. In just one district, 575 arsenic plants are having this
new technology installed. Innovations include filtering systems capable of handling high water
volumes. The plants are designed to remove arsenic above the allowable level (above a 3 µg/L)
in the water supply ingested by the immediate population. Water testing reveals the arsenic
levels after plant diffusion and removal of the heavy metal. Investigations show skin lesions in
approximately 1200 patients with ongoing research, a decrease in the number of affected
individuals (Chakraborti, 2001).
The major source of arsenic contamination in Chile’s rivers is industrial pollution, dating
back as far as 1971. Heart issues obtained for speciation analysis from arteries and veins with
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coronary heart disease help researchers to understand long-term effects from arsenic exposure on
vascular and cardio-vascular diseases (Roman et al., 2010; Shen et al., 2007).
Lung disease resulting from non-malignant adenomas in utero provides evidence of
arsenic-laden drinking water in many demographics, and is signaled by lowered respiratory
function, including shortness of breath. Lung cancer seems to be the most common cause of
death; adenomas may become cancerous later in life. Prolific levels upwards of over 10 ppb and
above are causations to the deleterious effects to humans and animals. Crepitations, chronic
bronchitis, and bronchiectasis have been noted as well (Dauphine, et al., 2011).
Early life exposure from drinking water in Chile caused 11.5% lower forced expiratory
volume in 1s (FEV1) (P = 0.04), 12.2% lower forced vital capacity (FVC) (P = 0.04), and
increases in breathlessness (prevalence odds ratio [POR] = 5.94%; confidence interval [CI] 1:36
– 26.0). Research suggests that irreversible respiratory exposures to arsenic mimics smoking
through adulthood, a known pulmonary complication. Northern Chile was laden with high
arsenic levels, as much as 870 µg/L, until a mechanical arsenic removal plant was installed.
Levels are being maintained at less than 10 µg/L (Dauphine et al., 2011). Chilean research
suggests that pulmonary testing barometers of FVC and FEV with the POR above 1.0 are
indicators of breathlessness, which identifies early life exposure to arsenic. The lung has a
propensity to accumulate arsenic, but not as much as the liver and kidneys, which are major
excretory organs (Dauphine et al., 2011).
Another disruption was estrogen signaling, evident in transplacental arsenic, inducing
hepatic carcinogenesis. In a particular study, arsenic was noticed only in female mice as a transplacental lung carcinogen. Human children exposed to arsenic in utero experienced increased
lung cancer incidence as well as chronic disease later in life. Studies associated with developing
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fetuses, cohort to maternal exposure to arsenic during day 8 to 18 of gestation led to multiple
incidences of tumor formations in the lungs (Petrick et al., 2009).
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Chapter 2.2 – Arsenic Methylation
White and red blood cells – aided by glutathione -- reduce As5+ to As3+ after being taken
up in the blood stream. A portion of As3+ is methylated in the liver by enzymatic Methyl group
transfer s-adenosyl methionine (SAM) to monomethylarsonic acid (MMA(V)) and dimethyl
arsenate (DMA(V)). These metabolites are excreted readily; methylation is an important form of
arsenic detoxification (ATSDR, 2009). Other research suggests that methylation is toxification
rather than detoxification of inorganic arsenic. Trivalent methylated arsenic metabolites of
MMA(III) and DMA(III) are created capable of interacting with cellular targets such as proteins
and DNA (ATSDR, 2009).
Research shows that methylation decreases with higher concentrations of arsenic.
Methylated arsenic species in urine is similar between siblings and parents, suggesting that
arsenic methylation can be genetically linked. Increased retention of arsenic in soft tissue is
amplified after methylation exceeds maximum capacity in the liver (ATSDR, 2009).
The percentages of excreted arsenic in urine are 50% dimethylated, whereas 25% is
monomethylated, and the remaining is inorganic arsenic with some possible variations. In cases
of higher urinary arsenic concentration, the methylated form is increased. In lower urinary totals,
the predominant form is inorganic arsenic (ATSDR, 2009).
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Chapter 2.3 – Arsenic Affects DNA and Genes
Postnatal arsenic exposures surpassing threshold accumulation levels, may act on DNA
and can cause cardiac abnormalities, arteriosclerosis, and chronic pulmonary disease. Other
genes of interest are extracellular matrix genes, cell motility genes, and those that regulate fetal
growth. Aberrant airway remodeling is noted in many diseases including emphysema, asthma,
idiopathic pulmonary fibrosis, tuberculosis, and bronchiectasis. Structural tissue changes from
injury with deregulated repair, alters extra cellular matrix, and creates deposition in the airway
wall (remnants of chronic inflammation) (Petrick, et al., 2009).
Arsenic exposure can lead to alterations in gene expressions by methylation which is
long-term, and heritable in offspring from arsenic exposure. Due to methylation and
bioaccumulation, embryonic development is altered, causing disease. Hyper-methylation of
arsenic causes teratogenic factors, and gene expression alterations. Analysis shows alterations of
MSH6, a protein recognized with DNA mismatches and mismatch repairs (Salnikow &
Zhitkovich, 2008). The protein increases in arsenic-exposed animals, an indication of increases
in repair. DNA repair proteins are also associated with apoptosis caused by arsenic exposures.
Arsenic was also identified as a developmental toxicant in the rat lung because it can reduce
body weight, fetal weight, and lung to body ratios as well as altering differentiation markers,
causing changes in fetal growth and development. The result may be underdeveloped fetal lungs
(Petrick et al., 2009).
Research suggests DMA(V), a metabolite of inorganic arsenic and a multi-tumor
promoter, is retained longer in the lungs than in other tissues. Early transplacental exposures in
both umbilical and maternal blood are similar, cause harmful effects after birth. A recent study in
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Argentina showed less metabolized DMA in children than adults. This particular finding also
showed higher death rates from lung cancer in early life (Dauphine et al., 2011).
The translocation of broken strands of DNA is linked to cancer and tumor proliferation.
Apoptosis (programmed cell death) prevents tumor initiation and development. Apoptosis is the
repair process to inhibited DNA cell structure. An example of DNA mix-ups are indicative of
cancer and the translocation of broken strands of DNA in pairing of partners from the wrong
chromosomes after breakage. When a heavy metal hits a DNA chromosome strand it splits, drifts
apart, and searches for the missing partner. Sometimes the missing partner pairs to another
unmatched chromosome strand becoming the precursor to mutations and cancer. Apoptosis or
the programmed cell death process that prevents tumor initiation and development is the repair
process to inhibited DNA cell structures, caused by Arsenic. Arsenic intensifies the onset of
lung, liver, and lymphatic cancers in the human body. Higher concentrations cause infertility and
miscarriages in women, infection resistance, and brain damage in both men and women. Arsenic
exposure also caused an IGF, an ER catalytic response, and pulmonary oncogenic process
activation in the fetal lung. (Shen, et al., 2007)
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Chapter 2.4 – Research Mediums
Testing of chick embryos injected with sodium arsenate showed congenital
malformations in day 8 to 9 of fetal gestation. A hamster injected with Sodium arsenate on day 8
of gestation in the implanted embryo undergoes axial orientation, rapid progression of
developmental stages, somite differentiation, neural tube closure, visceral arch formation, limb
bud formation, and embryonic heartbeat. Toxic levels in this particular study revealed that 30
mg/kg of arsenic would kill embryos in utero, with teratogenic effects occurring at 10 mg/kg.
Urogenital anomalies were noticed with sodium arsenate levels in female and male subjects.
Malformations were indicated in the uterus, ovaries, and testes, with unilateral and bilateral renal
agenesis (Ferm, 1977). During human pregnancy, arsenic trioxide (As2O3) manifests itself to
higher levels in the brain, kidneys, and liver crossing the placenta by day 8 of fetal gestation
(Ferm, 1977; Miller et al., 2002).
Studies initiated with mice and tetradecanoylphorbol-13 acetate (TPA) as a cohort
carcinogen causes hepatic carcinoma, as well as adrenal tumors. Female offspring showed an
increase in epithelial ovarian tumors from arsenic exposure in lieu of TPA as well as hyperplasia
of the uterus and oviduct. Gestational development is highly sensitive to carcinogenesis from
arsenic exposure. Drinking water is a common cause of contamination, resulting in threshold
limits of arsenic in humans. Mice born to maternally exposed females may show cancer effects
after birth, well into adulthood. Evidence of 10-day transplacental arsenic exposure produced
cancer effects in children (Waalkes et al., 2003).
DMA(V) is discharged through the bladder, thus cancerous bladder tumors are prevalent
in mice with accumulation from chronically ingested arsenic-laden water. The most profound
discovery to cancer was a cohort to DMAV and prenatal arsenic, followed by DMAV through
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adult life. The incidence rate of cancer was relatively low (17%), because spontaneous renal
tumors are rare in mice. Research also suggests that DMA(V), passing through the kidney as a
biomethylation metabolite, promotes tumors in rodents as well as in human fetal development
(Dauphine et al., 2011). Research suggests that maternal urine contains more MMA and As than
DMA(V), suggesting that methylated species have shorter half-lives of elimination than
inorganic forms (Hall et al., 2007).
Measures of blood arsenic metabolites, urinary arsenic metabolites, plasma folate, B-12
vitamins and homocysteine levels due to water concentrations across a wide spread
demographics can affect arsenic concentrations. A particular study showed a strong correlation
of 0.1-661.0 µg/L between maternal blood and cord total blood arsenic (r = 0.84; p < 0,0001).
Transplacental exposure reveals a correlation between levels of arsenic exposure and lower IQs
in children. Poor visual motor functioning was found in two groups of 6 and 10-year-old
children, although no distinction was made between prenatal and postnatal exposure in those
tested (Hall et al., 2007).
Folic acid enhances the methylation process. Prenatal folic acid supplements are
necessary in areas of higher arsenic concentrations in drinking water, aiding in arsenic
methylation. Folate and homocystines are especially necessary to arsenic methylation in fetal
development. Folate deficiency may cause spontaneous abortions, placenta abruption,
preeclampsia, and increased tissue retention in fetal gestation. If folate supplements are ingested
and maintained throughout pregnancy, postnatal concentrations in newborns are much higher
than the maternal pre-birth concentrations in mothers (Hall et al., 2007).
Since the liver is a site for DMA(V) biomethylation of inorganic arsenic, prenatal
exposure, and fetal gestation could possibly prime hepatic events to carcinogenesis, through
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inorganic arsenic biomethylation, thus promoting a product by hepatic metabolism derived from
gestational development. Fetal arsenic-induced liver cancer was greatly magnified by DMAV
exposure into human adulthood and caused renal cancer in mice (Tokar et al., 2012).
Arsenic destroys human cells and results in apoptosis, indicative of threshold limits.
As2O3 inhibits tumor causing apoptosis and cell death, for example, in breast cancer. Mechanistic
studies of multiple cellular and molecular indices such as MTT assay, apoptosis ELISA assay,
gene transfection, and invasion assays find reductions in cellular viability in arsenic oxidetreated cells in a dose-dependent cell, inherent in apoptosis in Notch 1 pathways. The Notch 1
pathways signal ligand-receptors that play a role in cell proliferation and apoptotic cell death,
differentiation, invasion, angiogenesis, tumor metastasis, and cancer stem cell renewal in human
breast cancer. Specific ligand and receptor genes have been identified in the actuality of Notch
signaling pathways. Research suggests that Notch target genes and Notch signaling pathways are
commonly associated with breast cancer. Notch 1,2,3, and 4 receptors as well as 5 ligands have
been identified and associated with breast cancer. Another research medium has determined that
high expression of Notch receptors and ligand observation is a weak indicator of breast cancer
(Roman et al., 2010).
Arsenic becomes the therapeutic factor in arresting apoptosis with As2O3, a reagent used
in the treatment of acute promyelocytic leukemia and other human cancers including breast
cancer. Molecular mechanisms yielding success of As2O3 treatment is somewhat elusive, but is
worthy of further research (Kile et al., 2012).
The problem becomes ubiquitous in nature due to inorganic arsenic exposure associated
with cancer risks of neurological, craniological, respiratory, hepatic, and hematological diseases.
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Inorganic arsenic is classified as a human carcinogen, especially in tests of fetal tissue. Research
potentially links in-utero exposures to chronic diseases in adulthood (Kile et al., 2012).
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Chapter 2.5 – Arsenic, Fetal and Embryonic Development
Blood concentrations of arsenic are too low and transient; some research suggests that
blood concentration is not a biomarker for chronic arsenic poisoning. Total arsenic amount in
urine has been in use as an indicator of recent arsenic exposure, because the kidney is the main
route of excretion of many arsenic species (Mazumder, 2000).
DMA(V) is carcinogenic in mice and rats. Transplacental arsenic exposure produces
internal tumors in mice offspring into adulthood. Research shows that the occurrence of lung
adenoma-carcinomas increased from 0 % to 20% in C3H mice with gestational inorganic arsenic
exposure, inducing pulmonary carcinogenesis promoted by phorbol esters (croton oil) in male
and female offspring. Evidence of transplacental factors indicative of arsenic crossing the rodent
and human placenta, acts on fetal development showing the lung as a target of arsenic
carcinogenesis (Shen et al., 2007).
Incidences of chronic cough, bronchitis, shortness of breath, and obstructive or restrictive
lung disease are lung perturbations targeted by arsenic, both carcinogenic and non-carcinogenic.
Estrogen signaling, evident in the trans-placental arsenic, may induce hepatic carcinogenesis. In
this particular study, arsenic was noticed only in female mice as a trans-placental lung
carcinogen. Children exposed to arsenic in utero experienced chronic disease, including cancer,
later in life (Petrick et al., 2009).

29

Chapter 2.6 – Rice and Arsenic
Rice absorbs arsenic from soil or water, thus high levels of arsenic from pesticides or
herbicides can alter crop yields, and contribute to arsenic bioaccumulation with human and
animal food ingestion. Brown rice showed a higher arsenic concentration in outer layers of the
grain, than white rice. Polishing white rice in the processing of the grain removes surface layers,
reducing the total organic and inorganic arsenic in the grain. Cereals are also higher in arsenic
concentration levels. Infants who consume 2-3 servings of rice cereals per day accumulate higher
concentrations of arsenic. Expectant mothers and their fetuses, as well as small children with
developing brains, are at a higher risk. Rice drinks can contain up to 4.5 µg/of arsenic per drink,
posing a risk for children under age 5. In utero exposures can often lead to lung cancer and
bronchiectasia later in life. The best testing measurement of arsenic is a urine analysis for MMA
and DMA(V) metabolites a few days after ingestion. A National Health and Nutrition
Examination Survey (NHANES) study from Dartmouth University researchers shows that rice
consumption contributes to increased urinary arsenic levels in children. Ingestion of seafood
containing AsB may confound results. The solution to arsenic consumption in rice is phasing out
the use of pesticides and fertilizers containing arsenic (Davis, et al., 2012).
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Chapter 2.7 – Arsenic in Flora
Deleterious effects to humans and animals through dietary intake of the toxic metalloid
and especially in marine aquatic settings are of great concern (Rahman et al., 2012). The arsenic
intake by phytoplankton, the most common primary producer in marine food chains, taking up
As5+ and reducing it to thermodynamic and unstable As3+ explains the ratio of As3+ to As5+ in
marine waters. Algae contain high concentrations of arsenic. Brown algae contains up to 230
µg/g-1; green algae up to 23.3 µg/g-1, and red algae up to 39 µg/g-1. Macro-algae contains 4.3-247
µg/g-1 more arsenic than green and blue-green macro-algae (8.0-1.10 µg/g-1 and 10.4-18.4 µg/g-1,
respectively) (Rahman et al., 2012).
Marine algae can hold up to 1000 times the arsenic concentration in surrounding waters,
contributing to the trophic transfer of arsenic to higher levels of the marine food chain, a real
threat to marine and human health. As5+ is taken in by phytoplankton and converted to As3+.
Phytoplankton plays a role in the speciation, biotransformation, and distribution of arsenic in the
aquatic food chain. As3+ redox reactions are common in aquatic settings, with methyl conversions
and organic arsenic such as arsenosugars (ASS). Marine phytoplankton show various
concentrations of arsenic, due to the biotransformation of arsenic species to methylated species
in the cell of the phytoplankton. As5+ is taken up by the phytoplankton and incorporated into the
carbohydrate compounds, and is biosynthesized to organoarsenicals. AsB increases in the marine
food chain at all trophic levels, and some research considers it a non-toxic form of arsenic
contained in seafood. Some research suggests that levels of AsB are elevated in crustaceans with
as much as 100 µg/g/L, posing little risk to the organism or its consumer. Some research also
suggests that the microflora of the crayfish degraded the AsB to TMAO, DMA(V),
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methylarsenic, and an unknown substance assumed to be dimethylarsenol acetate (DMAA)
(Devesa et al., 2005; Rahman et al., 2012).
Freshwater algae are lower in arsenic concentrations than marine algae. DMA(V) is
converted from inorganic arsenic through biological cycling in the marine environment. As5+ is
stable and the predominant species of arsenic in the aquatic environment transformed to As3+,
methylated to MMAA and DMAA by phytoplankton as well. Research suggests that the process
of conversion is a detoxifying process by phytoplankton with As5+ and the conversion to As3+
then released back to the water column as DMAA and MMAA. Bacteria is also a processing
factor in methylation and in mineralizing inorganic and organic arsenic (Hasegawa et al., 2001).
Mineralizing bacteria plays a role in the conversion of As5+ to As3+, DMAA and MMAA in
marine waters through demethylation and oxidation of methylarsenicals. Methylarsenicals are
the intermediate compounds in biosynthesis pathways of complex arsenosugars in marine
phytoplankton. Marine phytoplankton reduces inorganic arsenic to Methylarsenicals through
oxidative methylation from SAM to DMAA(V), and then reduced to DMAA(III). Archaea and
bacteria have the ability to transform inorganic arsenic to methylarsenicals (MMAA and
DMAA), to the organoarsenic species and then to arsenosugars (Rahman et al., 2012).
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Chapter 2.8 – Arsenobetaine Transformation
AsB is biotransformed at ambient and at lower temperatures with microbial action
through methylation by bacterial flora. The degradation pathway starts with cleavage of the
carboxyl methyl-arsenic bond of AsB, which generates TMAO, with subsequent cleavage of
methylarsenic bonds to form dimethylarsinate and methylarsinate (MA) (Devesa et al., 2005).
The biodegradation process ends with the formation of inorganic arsenic (AB, TMAO, DMA,
MA, As3+, and As5+). Another pathway for AsB is the cleavage of methylarsenic bonds,
generating DMAA. Degradation explains the lack of AsB in marine waters. This process was
executed by actively degrading bacteria strains in vitro, acting on AsB (Devesa et al., 2005). The
active AB transformation to DMA, MA, and U1 (possibly MMAA) occurred in the
hepatopancreas and tail, while trimethylarsonioriboside was also detected in the crayfish samples
tested (Devesa et al. 2005). As5+ is methylated in marine waters to the less toxic MA and DMA
(Contreras-Acuna et al., 2013).
Methylated trivalent arsenicals (MA(III) and DMA(III)) are more toxic than the
pentavalent forms, but are still carcinogenic. Marine organisms may then transform these
compounds into non-toxic species such as AsB found in seafood. AsB is the arsenic species with
traces of MA(V), DMA(V), tetramethylarsonium (TETRA -- an ion), and TMAO (ContrerasAcuna et al., 2013).
Dimethylarsonioribosides and trimethylarsonioribosides are the derivatives of
arsenosugars associated with the arsenic species in marine algae. In mammals, As5+ and As3+ are
more toxic than the methylated forms MA(V) and DMA(V). TMAO and TETRA are moderately
toxic as well. Research suggests that AsB, and Sc-arsenocholine are considered innocuous to
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humans. Arsenosugars may be toxic, causing carcinogenetic effects to humans and animals
(Contreras-Acuna et al., 2013).
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Chapter 2.9 – Arsenic in Fertilizers, Pesticides and Herbicides
In 1867, Paris green, an arsenic-laden rodenticide and insecticide, was used on potatoes
in Colorado (International Agency for Research on Cancer, 1991; Richardson, 2012). Lead
arsenate and London purple, other arsenic pesticides, both followed, and over 100 million people
were affected by arsenic and lead poisoning (Richardson, 2012). Recent usages fall into 2
categories: livestock drugs and pesticides. Arsenal livestock drugs like roxarsone, nitarsone,
carbasone, and arsanilic acid were used in turkeys, chickens, and swine, showing up in the livers
of treated animals. Roxarsone was used for weight gain and disease prevention (International
Agency for Research on Cancer, 2012). Pfizer removed it from the market in 2011 (FDA, 2011).
Most organic arsenals were banned in 2006, although some still remain. Outcry from industry
superseded environmental pushback and prevented complete eradication of agricultural arsenic
(Richardson, 2012). In 2009, all arsenals were set to be phased out by 2013, except monosodium
methyl arsenate (MSMA), which was approved for usage in the cotton growing process (IARC,
2012. However, nitarsone, carbarsone, and arsanilic acid are still legal, in use, and on the market.
(Richardson, 2012) Nitarsone is the last recognized arsenic drug being used in poultry farming
for weight gain, but by the end of 2015, the FDA will no longer allow its use (FDA, 2015).
Ironically, organic farmers cannot use arsenical pesticides, but can still use manure from
chickens fed arsenals or arsenal drugs, facilitating arsenic to farmlands (Agency for Toxic
Substances and Disease Registry, 2006). Most fertilizers include lime for pH adjustment with
nitrogen, phosphorous, and potassium depending on soil type (Gianessi, 2009).
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The EPA allows sewerage sludge containing arsenic up to 41,000 ppb to 41,000 ppm,
with farmlands calculating the sludge per hectare. The sewer sludge fertilizer may also be
utilized in home and garden use (Richardson, 2012).
At present, rice farms Louisiana use Round Up, a herbicide (Richardson, 2012), and
malathion, an organophosphate, as an insecticide. Malathion is an endocrine disrupter that
inhibits cholinesterase in insect brains, and causes death (ATSDR, 2003). Permethrin, a
pyrethroid synthetic chemical used as an insecticide, acts on neurons in insect brain, affecting
sodium channel activation, which also results in death of insects. Permethrin is not retained in
the soil as long as most insecticides, with a biological half-life of approximately 2 weeks (Becker
& Mergel, 2010). Confirm is an insecticide analogous to tebufenozide used in sugar cane.
Furadan, a carbamate, is a neurotoxic pesticide that inhibits cholinesterase.
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Chapter 2.10 – Arsenic Exposure
Water
Drinking Water – 10 µg/L (10 ppb) (WHO, 2001)
Soil Concentrations
Mean background concentrations – 5 mg/kg (low 1 mg/kg to high 40 mg/kg) (5,000 –
40,000 ppb) (WHO, 2001)
Mean sediment concentrations 5 – 3000 mg/kg (5,000 – 3,000,000 ppb) (WHO, 2001)
Higher levels occurring in areas of anthropogenic contamination (WHO, 2001)
Dietary Exposure
Most foods – < 0.25 mg/kg (250 ppb) (WHO, 2001)
Seafood, marine fish – 2.4 – 16.7 mg/kg (2,400 – 16,700 ppb) (WHO, 2001)
Mussels – 3.5 mg/kg (3,500 ppb) (WHO, 2001)
Crustaceans – 100 mg/kg (100,000 ppb) (WHO, 2001)
Grain – 1 – 21 µg/kg (1 – 21 ppb) (EPA)
White rice avg. – 114 µg/kg (114 ppb) (FDA)
Brown rice avg. – 59 µg/kg (59 ppb) (FDA)
Beer – 10/65 samples 15 – 26 µg/kg (15 – 26 ppb) (FDA)
Apple juice – 23 µg/kg (23 ppb) (FDA)
Dietary Intake – Ages
Infants under 1 year – 1.3 – 15.5 μg/day (1.3 – 15.5 ppb) (WHO, 2011)
2 years – 4.4 μg/day (4.4 ppb) (WHO, 2001)
25 – 30 years men – 9.9 μg/day (9.9 ppb) (WHO, 2001)
60 – 65 years women – 10 μg/day (10 ppb) (WHO, 2001)
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60 – 65 years men – 13 μg/day (13 ppb) (WHO, 2001)
Standards and Guidelines – Inorganic Arsenic
Minimum Risk Levels (MRL)
Oral Acute duration – 0.005 mg/kg/day – based on LOAEL – 0.05 mg As/kg/day (5 – 50
ppb) (ATSDR, 2007)
Oral Chronic duration – 0.0003 mg/kg/day – NOAEL – 0.0008 mg As/kg/day (3 – 8 ppb)
(ATSDR, 2007)
Chronic duration for skin and gastrointestinal (10 – 100 ppb) (ATSDR, 2007)
Rice – 0.2 mg/kg (200 ppb) (CAC)
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Chapter 3 – Cadmium
Cadmium (Cd) is an environmental pollutant, toxic to both humans and animals, and is
recognized as an occupational hazard worldwide. Industrial uses have caused great abundances
of the substance, and it negatively affects human organs from acute and chronic intake.
Cadmium has a biological half-life of 10-30 years, and is excreted slowly from the body while
accumulating in the kidney, blood, liver, and reproductive organs. Half-life of cadmium in blood
serum as compared to urine levels is a strong indicator of long-term cadmium exposure (Samuel
et al., 2011).
The MRLs for cadmium are: oral: intermediate, 0.0005 mg/kg/day (0.5 ppb) and oral:
chronic, 0.0001 mg/kg/day (0.1 ppb) (ATSDR, 2015). Cadmium causes nephro-toxicity,
immuno-toxicity, osteo-toxicity, teratogenicity, carcinogenicity, and reproductive toxicity.
Cadmium crosses the blood-brain barrier, affecting fetal development. Research suggests that
gestational cadmium treatment induces ovarian toxicity and reproductive dysfunction by way of
oxidative stress (Samuel et al., 2011). Pregnant and lactating females absorb and retain cadmium,
transferring it to the fetus. In pregnant rats, cadmium is known to induce placental necrosis and
hemorrhages, and to increase fetal deaths. Occupationally-exposed pregnant women showed
lower birth weights that correlated to cord blood and maternal cadmium concentrations. Mothers
of preterm infants showed a higher blood concentration of cadmium than those of full term in
areas with higher soil concentrations of cadmium (Samuel et al., 2011).
Adverse pregnancy outcomes such as reduced birth size, weight, or head circumference,
and preterm delivery are cadmium-related effects. Pregnant women in rural areas showed
increased concentrations of cadmium in placentas. Zinc transfer in cord blood is also associated
with elevated cadmium levels in placentas of pregnant women. (ATSDR, 2012) Cadmium
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disturbs or inhibits zinc transport of nutrients to the fetus, causing nutritional problems
associated with the placenta (Samuel et al., 2011).
When analyzing urine, cadmium levels are adjusted for specific gravity and creatinine
levels (ATSDR, 2012). Smokers are not usually included in cadmium case studies, unless
smoking is the epidemiological research medium in question. Urinary cadmium concentrations
are better biomarkers for accumulation levels in humans than cord blood indicators, associated
with inverse zinc transfers to the fetus (Samarawickrama & Webb, 1979).
Cadmium is an endocrine disrupter (Henson & Chedrese, 2004). Glucocorticoids convert
maternal cortisol to cortisone. In expectant mothers, cadmium decreases levels of 11B-IISD2,
while increasing cortisol levels, which may impair fetal growth. Cadmium may also interfere
with IGF and the IGF axis, affecting a sex specific factor. The effect of glucocorticoids seems to
be female-specific (Samarawickrama & Webb, 1979).
Cadmium effects on embryonic development and fetal gestation in rodents create a high
susceptibility to adverse effects. A single dose equivalent of 40 µM of CdC12/kg body weight
between day 17-21 of gestation resulted in destruction of the placenta and death of embryos in a
high proportion of pregnant rats (Samarawickrama & Webb, 1979). In a dose equal to 1.05 to
1.77 mg/kg administered to a Wistar-Portion strain of female rats within a 21-day gestational
period, flush extremities, vasodilatation, rapid shallow respiration, apathy, and flaccidity of
muscles occurred after 1,D7,0 drops were administered to gravid and non-gravid animals. Deaths
occurred within 16-24 hours; with higher doses, death occurred within 6 hours. Deleterious
effects were sub-pleural hemorrhage of the lung. Vaginal bleeding occurred in pregnant animals
at 8 hours, indicating placenta damage. Seizures preceded respiratory paralysis and muscular
flaccidity (results of neuromuscular block) (Samarawickrama & Webb, 1979).
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Observations of the liver and kidneys shows excess fluid as well as an increase in blood
flow. The placenta loses architecture and turns into a blood clot. The proximal tubules show
complete degeneration, while glomeruli tubules are spared. Cadmium causes congenital
deformities in rats, mice, and hamsters during periods of gestation. Teratogenic effects were
prevalent in gestational periods of 8-15 days in rats receiving a 1.25 mg dose of cadmium,
inducing deformities in a high percentage of fetuses. Encephalitis is most noticeable in 80% of
fetuses after delivery by C-section. Umbilical hernias are present in 45% of the fetuses.
(Samarawickrama & Webb, 1979).
Cadmium distribution to the embryo on day 12 of gestation interferes with the placental
function, and the zinc transport mechanism demand to the placenta. A dose of 0.5 mg/kg after
four hours produces inhibition of zinc across the placenta by as much 50%, and the developing
brain is also affected. Thymidine incorporation into the embryo’s DNA is also inhibited at 4-20
hours, but is similar to controls in the four hour interval. DNA synthesis is inhibited; RNA and
protein production are unaffected (Samarawickrama & Webb, 1979).
Maternal cadmium retention from oral exposure during gestation is double the
concentration observed in non-pregnant mice, but a small fraction of cadmium is still transferred
to the fetus in exposed mice. Results show that chronic cadmium exposure causes behavioral
changes in mice offspring. Neuro-chemical parameters are being explored to the actual effects of
cadmium on growing pups, with long-term effects on brain functions during childhood (Gupta, et
al., 1991).
Assays were performed with acetyl cholinesterase activity in the homogenate, using
acetyl thiocholine iodide substrate in female albino rats of the Durkey strain. The acetyl
cholinesterase enzyme was increased by 13% in cadmium-exposed pups at ages 14 and 21 days
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compared to control rats. The sodium-potassium pump production in rat controls increased
significantly (20%) from age 7 to 21 days. The enzyme 2', 3'-cyclic nucleocide 3'phosphohydrolase (a myelin protein) showed an increase from 7 to 21 days in control animals, as
compared to and the same at postnatal 7 days, but lower by 29% and 24% at 14 and 21 days, as
compared to the control. The 5'-nucleotidase (enzyme that catalyzes RNA reactions) was
identical in control 7 to 14 day-old pups, increased in 21 day-old controls, but was 21% lower in
experimental pups. Overall, activity of this enzyme was lower in gestational-exposed pups
(Samuel et al., 2011).
Cadmium causes changes in production of ovums and in regulation of hormones secreted
by the pituitary and hypothalamus glands. It also causes a decrease in body and ovary weight in
cadmium-treated animals. Impaired gonadal development causes gonadotropin levels to
decrease. Steroid hormone production is also impaired, decreasing testosterone, estradiol, and
progesterone in cadmium treated rats (Samuel et al., 2011).
Cadmium inhibits germ cell production in developing human female and male gonads.
Research suggests that a 1 µM concentration (a very low exposure) decreases human germ cell
development, showing extreme sensitivity of germ cells to cadmium exposure. In other human
cells like hepatocytes and neuroblastomal cells, a 100 µM concentration triggers deleterious
effects. One µM of cadmium decreases germ cell counts after 3 days of exposure through
apoptosis, but does not alter germ cell proliferation. Cadmium alters DNA repair in proliferating
germ cells, causing deleterious effects to meiotic cells undergoing apoptosis. Oocytes in mice
exposed to cadmium decreased due to apoptosis (Angenard et al., 2010).
Brain enzymes increase from birth to adulthood due to cellular development fractions,
reflecting the increased functional brain activity. Cadmium inhibits a wide variety of
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mitochondrial functions, including SDH-sorbitol dehydrogenase. In 21-day-old pups, enzymes
were inhibited by cadmium. Research indicates that lower level exposure to cadmium causes
behavioral problems at 60 days. In utero exposure to cadmium causes changes of neurochemicals
in the brain, responsible for functional developmental changes (Gupta et al., 1991).
Pancreatic cancer is another side effect of cadmium exposure in humans. South Louisiana
has experienced a high mortality rate from pancreatic cancer since 1950. Information obtained
from Region 4 Tumor Registry of Louisiana, provides demographic information (Luckett et al.,
2012). The Acadiana region from 2000-2004 had the highest incidence rate of cancer with 15.9
cases per 100,000 residents. Cadmium causes trans-differentiation of pancreatic cells and
increases synthesis of DNA in the pancreas. Cadmium oxide is released during cigarette burning,
showing 3-4 times higher accumulation levels in smokers versus non-smokers; cigarette smoking
is an established risk factor of pancreatic cancer, providing 1 to 2 micrograms in each cigarette
(Luckett et al., 2012).
Phosphate fertilizers and sewerage sludge contains cadmium, while cadmium chloride is
used in the preparation of some pesticides, raising cadmium levels in soil. Household dust testing
in South Louisiana in rural and urban areas showed higher mean-rates of cadmium levels.
Cadmium is released in gasoline and lubricating oils during fossil fuel combustion. Welders and
pipe fitters are subjected to fumes generated in shipyard construction. Research suggests, cancer
is prevalent in South Louisiana especially from cereal and rice products, accounting for 66%
from plants and 33% from animal sources (Luckett et al., 2012).
Consumption of red meat and pork are both associated with a higher risk of cancer, due
to cadmium intake. Research suggests that grain feed, especially that fed to pork, may have a
higher cadmium level. Red meat is a product of grass grazing, indicating less cadmium intake.
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Cadmium exposure beyond threshold limits is transmitted from females to fetuses,
causing DNA inhibition and increasing percentages of cancer. Fetal gestation is often times the
beginning of cadmium accumulation, often becoming cancerous after age 40. The body has no
efficient excretion method for removal of the heavy metal, thus it accumulates in utero to
adulthood in tissues and organs. Cadmium binds to metallothionein (MT) in low levels and is
usually deposited in the pancreas, liver, kidneys, and testes (ATSDR, 2012). Cadmium competes
with zinc in biochemical reactions. Sharing many physical and chemical properties, biological
systems that require zinc are often replaced by cadmium, introducing the formation of tumors
(Schwartz & Reis, 2000).
Dietary cadmium is associated with carcinogenesis and cancer-related illnesses. In
western countries, vegetables and cereals contain higher sources of cadmium. Far east countries
like Japan show a higher intake in rice and rice products. Low levels of cadmium have a direct
effect on cancer related illnesses in the general populations. As much as 80% of cadmium intake
is 8 to 25 µg/day from food sources. Gastronomical intake is lower at approximately 5 % (Cho et
al., 2013).
Intake is relative to lifestyle, dietary habits, and absorption rate. Populations in certain
geographical locations are more prone to exposure, due to higher concentrations. Louisiana has a
higher intake of cadmium from a diet containing greater proportions of rice, pork, and beef from
grain fed animals. Higher exposure creates much greater intakes for cancer related illnesses in
Louisiana. Recent studies show biomarkers related to cadmium risks and cancer illnesses.
Studies show higher rates of urinary cadmium, correlating to breast cancer in breast tumor tissue
(Cho et al., 2013). Limiting rice and vegetable products as well as pork and red meat in areas
with higher levels of cadmium contamination will limit intake. Educating populations within
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demographics subject to higher levels of cadmium will help control cancer caused by the heavy
metal (Luckett et al., 2012)
Cadmium is known to cause cancer by other pathways such as aberrant gene expression,
oxidative stress, inhibition of DNA damage repair, and inhibition of apoptosis (Xu et al., 1996).
Other studies have shown that cadmium mimics steroid hormones as well as androgen and
estrogen binding, while activating steroid receptors (Johnson et al., 2003). Research suggests that
cadmium may facilitate other carcinogenic compounds to induce cancer as well, although
carcinogenesis can be caused solely from cadmium exposure (Cho et al., 2013).
Smokers have a higher cadmium level in the lung than non-smokers. The lung is a major
target organ, accumulating and absorbing cadmium with a nine-and-a-half-year half-life.
Occupational cadmium affects approximately 500,000 workers in the US. Long-term exposure to
cadmium causes emphysema, by cadmium binding to thiols, MT, and glutathione. Emphysema
by definition is "a pathological lesion of abnormal enlargement of the respiratory airspaces, very
common in industrial workers chronically exposed to cadmium'' (Zhao et al., 2006).
Chromosomal aberrations increased in the lymphocytes of cadmium exposed workers (ATSDR,
2012). After attaining thresh-hold levels, cancer causing effects are endocrine interruption, DNA
synthesis, and aberrant gene expression.
Cadmium (2+) and zinc (2+) ions have the same electronic structure of the valence shell.
Cadmium acts as a zinc antagonist. Both compete for the metal-binding protein MT. Cadmium
has a greater affinity and binds to MT, reducing distribution of the metal to the tissues (other
than the liver, where it does accumulate) and promotes elimination by way of synthesis. It causes
renal toxicity. Free cadmium is toxic; bound cadmium is nontoxic (Valko et al., 2005; ATSDR,
2012).
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Cadmium is absorbed by blood plasma, binding to albumin and other high weight
proteins. The liver takes it up and induces MT with sulfhydryl groups, binding cadmium
efficiently with a small amount entering blood circulation. Cadmium-metallothionein is filtered
in plasma through the renal glomeruli and reabsorbed in proximal tubules thus accumulating in
the kidney. Fourteen days to 1 year of chronic exposure creates a major burden in the kidney.
Lysosomes of the tubule cells break down the cadmium-metallothionein complex; free cadmium
induces renal synthesis of MT, binds to cadmium and decreases in toxicity. When synthesis
capacity of MT with cadmium is exceeded, free cadmium accumulation increases. Some
cadmium from the kidneys is continuously released into the blood stream, crossing the bloodbrain barrier with smaller proportions and distributing to other organs, such as the pancreas and
testes (Luckett et al., 2012).
Cadmium disrupts normal endocrine function by inducing oxidative stress in the
reproductive organs such as the ovaries and testes (Thompson & Bannigan, 2008; Siu et al.,
2009). Mammalian studies show reduced sperm count as well as poor semen quality in men
exposed to cadmium (Benoff et al., 2000; Siu et al., 2009).
The main organs affected by high-dose, acute exposure of cadmium with chronic effects
are the kidneys, bones, and especially the lungs. Cadmium is primarily excreted in the urine,
with some released through bile, pancreatic juice, and feces. Elimination of cadmium from the
kidney is very slow, with the highest level of cadmium concentration in the renal cortex
(ATSDR, 2012).
Cadmium catalytically increases oxidative stress in the formation of the reactive oxygen
species (ROS), also increasing lipid peroxidation, depleting glutathione, and protein-bound
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sulfhydryl groups, while eliminating the protective junction of nitric oxide formation (Valko et
al., 2005). Cadmium also stimulates the production of inflammatory cytokines.
DNA strand breaks cause mutations aligned with chromosomal damage, cell
transformation, and impaired ability to self-repair (Beyersmann & Hartwig, 2008). Cadmium has
been found to cause chromosomal damage in animal experiments with subcutaneous
administration. Cadmium causes cancer of the lung, kidney and prostate. (ATSDR, 2012)
Blood levels of cadmium are monitored for exposure. Blood levels decrease after
exposure and a slow elimination commences, eliminating cadmium from the kidney and body.
Cadmium is measured in whole blood erythrocyte, serum bound levels, and metallothionein
bound cadmium in plasma. (ATSDR, 2012)
Urine is used as a primary indicator of exposure. A 24-hour specimen is used to show the
relationship to and variation between the cadmium count in urine and the kidney. A substantially
high cadmium content in the renal cortex is enough to cause tubular damage. Due to cadmium
content in smokers, there is a variation between non-smokers below 1µg/g creative (-1µg/I or
µg/24 hr) (ATSDR, 2012). Other means of determining cadmium levels in the liver and kidney
are the neutron activation analysis and x-ray florescence. These can detect the damage due to
long-term exposure (ATSDR, 2012).
Cadmium overexposure produces skeletal effects, with excess excretion of calcium
causing bone pain, osteomalacia and osteoporosis (Luckett et al., 2012). Bone effects were first
recognized during WWII in Japan with renal dysfunction and osteodystrophy in postmenopausal,
multiparous women. They were living downstream from an old lead and zinc mine, and drinking
from a contaminated water supply. Osteomalacia (referred to in Japan as “Itai-itai disease” or
“Ouch-Ouch disease”) painfully manifests in the bones (Yoshida, 1999). Pregnancy, lactation,
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and menopausal hormone depletion caused by bone changes may have exacerbated cadmium
osteotoxcity (ATSDR, 2012). In osteomalacia, cadmium is exchanged for calcium in the bones,
and decreases bone formation. This leads to osteoporotic bone loss and increased bone fragility
at low bone cadmium concentrations, and marked osteopenia as well as decreased bone density
(Yoshida, 1999; ATSDR, 2012). Bone damage from a vitamin D inhibition or metabolism
deficiency due to cadmium may occur hours after exposure also causing parathyroid hormone
(PTH) and vitamin disturbances. Serum parathyroid hormone serum increases as well (ATSDR,
2012).
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Chapter 4 – Copper
The recommended daily allowance (RDA) for copper is 0.9 mg, but the median intake
from a typical U.S. diet ranges from 1-1.6 mg/day. The safest highest intake of copper for
chronic exposure is 10 mg/day. Copper is found in shellfish, organ meats, nuts, beans, and
cocoa (New Hampshire Department of Environmental Services, 2013). Copper is present in all
living cells and is associated with many oxidation processes. Through oxidation, copper exists
in one of two ionic states: cuprous (Cu) and cupric (Cu2), which is more abundant. Copper
binds to proteins such as ceruloplasmin, albumin, and transcuprein, which are all copper
transport vehicles, and to the blood-clotting factor V. MT sequesters and stores the metal in
cells (Linder et al., 1998).
Copper is absorbed through the duodenum and the stomach. Half of copper
absorbed is taken in through the intestinal mucosa then carried by albumin to the liver.
Ceruloplasmin, albumin, and transcuprein are complexed with copper and transported to
tissues. Ascorbic acid inhibits the absorption of copper. Excretion occurs through bile,
sweat, urine, and saliva (Wapnir, 1998).
Blood levels of copper rise rapidly after ingestion, bound to albumin, then released
to other carriers for cell specific uptake. Transcuprein transports copper to the liver and
kidneys, and reemerges into the plasma, now bound to the ceruloplasmin. 60-95% of
copper is found bound to ceruloplasmin (Wapnir, 1998).
Ceruloplasmin does not enter the cell, but copper does via a carrier-mediated
process. Adenosine triphosphatase (Cu-ATP) is a binds copper and transports it in and out
of cells. Liver is a storage site and route for excretion in the bile system (Dijkastra et al., 1995).
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Ceruloplasmin is synthesized in the liver. Indicators of copper exposure are
detected in serum and urine, as well as ceruloplasmin levels. Blood proteins and MT bind
copper, which is an essential component of metalloenzymes. Impairment of
metalloenzymes can cause anemia, infections, bone abnormalities, hypopigmentation of
hair, and hypotonia (Dijkastra et al., 1995).
Copper toxicity results in gastrointestinal symptoms, hepatic necrosis, and even
death. Wilson's disease (a rare inherited genetic disorder) is caused by excessive
accumulation of copper in the liver, brain, kidney, and cornea (Ferenci et al., 2015).
Accumulation in the liver results in impaired biliary excretion of copper. It is common
in Hungary, Yugoslavia, and Italy (especially in Sicily) (Loudianos et al., 2003; Adhami
& Cullufi, 1995). Brass vessels for feeding and drinking in children can nurture jaundice, liver
disease, fibrosis, and cirrhosis from copper contamination; in western countries idiopathic
copper toxicosis occurs from milk stored in copper vessels (Loudianos et al., 2003;
Adhami and Cullufi, 1995).
In children, symptoms show up by age 4 in abnormal posture or stiffness of legs
and arms. Other symptoms are confusion, delirium, dementia, ataxia (impairment of
muscle coordination), emotional changes, and abdominal distension (Loudianos et al.,
2003). Sufferers of Wilson's disease also experience personality changes, phobias,
neuroses, slower facial expressions, arm tremors, uncontrollable or jerky movements,
vomiting blood, jaundice, yellow eye color, and overall weakness (Ferenci et al., 2015).
Copper is associated with Menkes disease, a sex-linked inherited characteristic,
primarily affecting male infants. It is referred to as “Pili torti,” "steely haired disease" or
"kinky hair syndrome" where the hair is kinky, lacking color, or steel colored, and very easily
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broken hair shafts (Choudhary et al., 2012). There is distinct abnormality in the hair of males,
whereas in females only half of hair follicles will be noticeably abnormal, but readily
noticeable under a microscope (Shapira et al., 1992). In Menkes disease, mutation of the
ATP7A gene inhibits the distribution of copper to body cells. Copper accumulates in tissues
such as the small intestines and kidneys (Choudhary et al., 2012). The brain usually has low
levels of copper. A decrease in the supply inhibits the usefulness of many copper-containing
enzymes necessary for the structure and function of bone, skin, hair, and blood vessels, as well
as the central nervous system. Signs of Menkes disease and occipital horn syndrome are
caused by reduced activity of these copper-containing enzymes. Lack of muscle control
(hypotonia), seizures, degeneration of the cerebral cortex, and mental degeneration sometimes
yields death by age 5 (Choudhary et al., 2012; Tang et al., 2006).
High or high normal zinc and low ceruloplasmin levels can cause spastic gait,
dysfunction and polyneuropathy. Normal or near resoration of copper levels can be achieved
with supplements and prevention of neurologic deterioration, which can be caused by prior
gastric surgery, excessive zinc ingestion, and malabsorption. Likened to zinc deficiency,
hematological effects of copper deficiency can inhibit incorporation of iron into heme
molecules (Wapnir, 1998).
Copper is essential in certain redox reactions, and deficiency can cause toxicity and
impairment of the body's oxidative system. This will inhibit the antioxidant defense system
of cells, possibly causing cardiovascular rupture, weakening of cross-linking, fibrosis of
the cardiac muscle, heart atrophy, aortic syndrome-aneurysm, and increased risk of
disruption of normal cardiac rhythm, as well as hemopoietic, vascular, skeletal, and CNS
damage. (Kumar, 2006)

51

Chapter 4.1 – Menkes Disease
Menkes disease is indicative of neurological defects in a group of enzymes requiring
copper. Menkes disease was first described in a single family in 1962. The rate of occurrence is
1/140,000 to 1/300,000 with known neurogenic defects. Idiopathic occurrences are poorly
comprehended. Asian research has calculated the occurrence at 1/50,000 to 1/300,000 of live
births, affecting males more often than females (Lin et al., 2014; Kaler, 2011). Research has
found that mutations in the ATP7A gene causes a loss of copper in the body’s cells (Zlatic et al.,
2015). Pathogenic mechanisms include neuronal pathogenesis of copper from a micronutrient to
a toxicant, causing cell death triggered by altered metabolic homeostasis mechanisms and cells
using neurotoxic anticancer agents, such as platinum, to bind to ATP7A (Zlatic et al., 2015).
Alzheimer’s disease and Parkinson’s disease are further complications of Menkes disease
due to impairment in molecular networks. Menkes disease causes hypotonia, failure to thrive,
focal and generalized seizures, impaired cognitive development, and brain atrophy. Menkes
disease also causes sagging infant facial appearances, arched palates, laxity of skin, reduced bone
density, bladder diverticula, and aneurysms. Gray and white brain matter atrophy is another
complication: neuronal cell loss in the cerebral cortex, hippocampus, striatum, hypothalamus,
and thalamus can occur. Astrocytosis is indicative of cell loss in the cerebral cortex (Zlatic et al.,
2015).
ATP7A copper extrusion supplies the body with copper transport across intestinal
enterocytes, accounting for severe systemic copper deficiency in Menkes patients (Zlatic et al.,
2015). Color exemplification and hypo-pigmentation is also observed (Zlatic et al., 2015).
Research suggests that early diagnosis and copper supplements can improve neurological
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problems associated with the disease, but not the physiological. No effective cure has been
reported to date (Lin et al., 2014; Kaler, 2011).
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Chapter 4.2 – Wilson’s Disease
Wilson’s disease occurs usually in the second or third decade of life, with 46 of 122
patients (3.8%) displaying symptoms after 40 years of age. Cellular level indicators of
pathogenic ATP7B amino acid substitutions may vary. Wilson’s disease has also been reported
in as early as 9 months of age. Pediatric physicians should be aware of spasmodic muscle cramps
and myopathy in children. Symptoms of wing-beating, tremor, or flapping tremor combined with
dysarthria, suggest the diagnosis of Wilson’s disease. The most symptomatic indicator is a
dystonic tremor. Aysarthria is combined with slow tongue movements, orofacial dyskinesias,
involuntary grimacing with open mouth, and contracted upper lip (Bandmann et al., 2015).
Increased copper intracellular concentrations can create oxidative stress, free radical formations,
and mitochondrial dysfunction. These combined effects can lead to cell death in hepatic and
brain tissue, and in other organs (Bandmann et al., 2015). A large statistical study in Asia
revealed the prevalence of Wilson’s disease; a ratio of 1/1500 – 1/3000 based on concentrations
in serum of the copper-carrying protein ceruloplasmin was established (Bandmann et al., 2015).
Research suggests that three distinct neurological disorders are usually present in
Wilson’s disease: dystonic syndrome, ataxic syndrome, or a Parkinsonian syndrome with most
patients presenting a combination of symptoms. Other movement impairments are hypomimia,
shuffling gait, impaired fine finger movements, and foot tapping (Bandmann et al., 2015).
Analysis of urine in a 24-hour interval to determine copper excretion is an important
diagnostic test for Wilson’s disease. In asymptomatic children, 40 µg/24 hr (0.64 µM/24 hr) are
suggestive of Wilson’s disease. Two mutations associated with ATP7B in Wilson’s disease can
be detected and confirmed clinically if the entire coding region and adjacent splice sites are
sequenced. This process can expose and analyze the disease in families with a higher propensity
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and prevalence of the disease. Treatment of the disease includes two phases of chelation and decoppering therapy, or botulinum toxin injections or primidone for dystonia (Bandmann et al.,
2015).
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Chapter 4.3 – Copper Exposure
Water
Drinking water – 1.3 mg/L (1,300 ppb) (ATSDR)
Bottle water – 1.0 mg/L (1,000 ppb) (ATSDR)
Dietary Intake – Ages
Recommended Daily Allowance
Infants 0 – 6 months – 200 µg/day (200 ppb) (NA, 2001)
Infants 7 – 12 months – 220 µg/day (220 ppb) (NA, 2001)
1 – 3 years – 340 µg/day (340 ppb) (NA, 2001)
4 – 8 years – 440 µg/day (440 ppb) (NA, 2001)
9 – 13 years – 700 µg/day (700 ppb) (NA, 2001)
14 – 18 years – 890 µg/day (890 ppb) (NA, 2001)
≥ 19 years – 900 µg/day (900 ppb) (NA, 2001)
Pregnancy ≤ 18 years – 1,000 µg/day (1,000 ppb) (NA, 2001)
Pregnancy 19 – 50 years– 1,000 µg/day (1,000 ppb) (NA, 2001)
Lactation ≤ 18 years – 1,300 µg/day (1,300 ppb) (NA, 2001)
Lactation 19 – 50 years – 1,300 µg/day (1,300 ppb) (NA, 2001)
Estimated Average Requirements
1 – 3 years – 260 µg/day (260 ppb) (NA, 2001)
4 – 8 years – 340 µg/day (340 ppb) (NA, 2001)
9 – 13 years – 540 µg/day (540 ppb) (NA, 2001)
14 – 18 years – 685 µg/day (685 ppb) (NA, 2001)
≥ 19 years – 700 µg/day (700 ppb) (NA, 2001)
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Pregnancy 14 – 18 years – 785 µg/day (785 ppb) (NA, 2001)
Pregnancy 19 – 50 years – 800 µg/day (800 ppb) (NA, 2001)
Lactation 14 – 18 years – 985 µg/day (985 ppb) (NA, 2001)
Lactation 19 – 50 years – 1,000 µg/day (1,000 ppb) (NA, 2001)
Tolerable Upper Intake Levels
Infants 0 – 6 months – ND* (NA, 2001)
Infants 6 – 12 months – ND* (NA, 2001)
1 – 3 years – 1,000 µg/day (1,000 ppb) (NA, 2001)
4 – 8 years – 3,000 µg/day (3,000 ppb) (NA, 2001)
9 – 13 years – 5,000 µg/day (5,000 ppb) (NA, 2001)
14 – 18 years – 8,000 µg/day (8,000 ppb) (NA, 2001)
≥ 19 years – 10,000 µg/day (10,000 ppb) (NA, 2001)
Pregnancy 14 – 18 years – 8,000 µg/day (8,000 ppb) (NA, 2001)
Pregnancy 19 – 50 years – 10,000 µg/day (1,000 ppb) (NA, 2001)
Lactation 14 – 18 years – 8,000 µg/day (8,000 ppb) (NA, 2001)
Lactation 19 – 50 years – 10,000 µg/day (10,000 ppb) (NA, 2001)
* ND = Not determinable due to lack of data of adverse effects in this age group
and concern with regard to lack of ability to handle excess amounts. Source of
intake should be from food only to prevent high levels of intake.
Standards and Guidelines
Minimum Risk Levels (MRL)
Oral Acute duration – 0.01 mg/kg/day gastrointestinal (10 ppb) (ATSDR)
Oral intermediate duration – 0.01 mg/kg/day gastrointestinal (10 ppb) (ATSDR)
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Chapter 5 – Zinc
Zinc and Copper are nutrients required for normal physiological function in the
human body. The bottom of the U-shaped curve in Figure 1 represents the region of
homeostasis -- the dose range results in neither deficiency nor toxicity.
Figure 1 – Homeostasis

Deficiency

Toxicity
►
Dose

(Calabrese & Baldwin, 2001)
Genetic expression, cell division, protein synthesis, immune functions, wound healing,
and normal growth are all essential for the function of greater than two hundred enzymes.
Activity and structure require zinc for carbonic anhydrase, alkaline phosphate, alcohol
dehydrogenase, copper-zinc superoxide dismutase, carboxypeptidase, RNA polymerase, and
reverse transcriptase (Calabrese & Prasad, 1983; Nriagu, 2007).
Zinc inhibits copper absorption through MT in the genetic treatment of Wilson's disease
in which copper accumulates in cells. Absorbed copper is bound by MT in mucosal cells,
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preventing its transport into the body. Copper displaces zinc from MT and caused copper
deficiency (Avan & Hoogenraad, 2015).
Zinc is found in erythrocytes (87% carbonic anhydrase, a major binding site) in plasma
with two-thirds of zinc bound to albumin in the diffusible form, and the remainder bound to
alpha2-macroglobulin (non-diffusible). Binding sites for zinc are limited in number, with these
two blood proteins regulating the amount of zinc retained in the body -- crucial for immune
function. Zinc is lost from the body through hair loss, saliva, sweat, urine and feces (ATSDR,
2003; Nriagu, 2007). MT production increases in response to increased zinc levels,
regulating it by binding to the metal to aid in excretion through the feces (ATSDR, 2005).
The Food and Nutrition Board (FNB) at the Institute of Medicine of the National
Academies developed dietary reference intakes (DRI). The RDA for zinc is 15 mg/day.
Adequate intake (AI) is established when there is insufficient evidence to develop RDA; a level
is assumed to ensure nutritional adequacy. 40 mg/day is the tolerable upper intake level (UL)
(Fosmire, 1990; Nriagu, 2007).
Research suggests that zinc supplements aid in weight gain and growth factors in children
(Brown, 1998). Lack of zinc supplementation can create adverse effects on fetal brain
development and function in children (Merialdi et al., 1999). However, zinc supplements can
cause long-term effects when taken 1-8 years. 2 mg/kg/day of zinc sulfate for 10 months
caused anemia in humans. 50 mg/day of zinc gluconate for 10 weeks caused a reduction
(47%) in erythrocyte superoxide dismutase activity in hematocrit and serum ferritin. Zinc
induces copper deficiency and severe hematologic effects, including anemia. Ringed
sideroblasts from iron deposits occur in erythrocyte precursors, and a decrease in
ceruloplasmin. A study of healthy men given a dose of 200 mg of zinc for 6 weeks showed
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a reduction in lymphocyte stimulation response. The study also showed reduction response
to phytohemagglutinin, chemotaxis, and phagocytosis of bacteria by segmented
neutrophils. High levels of zinc (300 mg or higher) causes anemia by decreasing highdensity-lipoproteins (HDL – “good” cholesterol), and pancreatic damage. It also increases
lower-density-lipoproteins (LDL – “bad” cholesterol), although total cholesterol was
unaffected from baseline levels (Fosmire, 1990; Nriagu, 2007). Acute pancreatitis followed
the ingestion of liquid zinc chloride (Nriagu, 2007).
Signs of zinc toxicity include vomiting, diarrhea, lack of appetite, abdominal pain,
headaches, and lethargy. Other deleterious effects include pale gums, acute kidney failure,
loss of libido, impotence, prostatitis, ovarian cysts, menstrual problems, and muscle spasms
(Fosmire, 1990; Nriagu, 2007).
Zinc toxicity causes gastrointestinal distress from beverages stored in galvanized
cans. Inhalation of zinc fumes causes metal fume fever (MFF), which manifests as chills,
profuse sweating, and weakness, lasting approximately 24 hours. This is very common in
workers on Mondays after holidays with consumption of beverages affected by zinc
containers. MFF is also common with welders who work with galvanized zinc metal
structures (Wardhana & Datau, 2014). The North American diet contains approximately 815 mg/day from data obtained by way of the 1988-1994 National Health and Nutrition
Examination Survey (IOM, 2001). Zinc is absorbed primarily in the small intestine, with
the duodenum absorbing approximately 60%, the ileum 30%, the jejunum 8%, and 3 % by
way of the colon and cecum (Methfessel & Spencer, 1973; Davies, 1980).
Animal studies conducted on high proportionate amounts of zinc exposure in the
2000 ppm range showed epiphyseal inhibitions in the long bones of the hind legs of
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laboratory rats. The study also showed paralysis of the hind legs, curvature of the lower
leg, retarded epiphyseal closure of the proximal end of the tibia, proliferation of
epiphyseal cartilaginous tissue, and irregular arrangement of chondrocytes (Halliasos et
al., 2007; Cui et al. 2004; Lelie et al., 2011).
Diseases such as amyotrophic lateral sclerosis (ALS), a progressive
neurodegenerative disease, results in a loss of upper and lower motor neurons, and eventually
fatal paralysis. Studies showed that Zn 2+ induced changes in neurotrophins, or proteins that
regulate development, maintenance, and function of neurons. Alzheimer's disease studies
show higher levels of zinc in the olfactory region, hippocampus, and amygdala, causing
neuron death. Zinc also induces accumulation of toxic free radicals that leads to neuronal
necrosis. A research study of 11 cases of multiple sclerosis in workers with 10 years of
exposure in a manufacturing plant showed higher serum levels than control groups (Halliasos
et al., 2007; Lelie et al., 2011).
Fixodent and Poligrip (adhesive pastes for dentures) were analyzed for zinc
concentrations. A high level of 17 – 34,000 µg/gm zinc was detected. The patient used two tubes
of denture cream per week for 2 years. The result of over exposure to zinc included numbness
and weakness of arms and legs, often leading to wheel chair dependency (Nations, 2008).
Another patient in the study wore dentures for many years, using 3 tubes a week. The patient
experienced hand numbness, impaired balance, severe distal upper extremity weakness, atrophy,
hyper-flexia, abnormal extensor plantar responses, and decreased pinprick sensations in the
hands. A brain MRI showed sub-cortical lesions (Nations, 2008).
Zinc deficiency causes severe health effects and is a co-factor of 200
metallonenzymes that are required in immune function and for vitamin A metabolism. Zinc
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deficiencies also cause delayed sexual maturation, pellagra, iron folate deficiency,
ulcerative colitis, malabsorption syndromes, and chronic renal disease disorder. Other effects
are growth retardation, loss of appetite, hair loss, impotence, hypogonadism, eye and skin
lesions, weight loss, delayed wound healing, taste abnormalities, and mental lethargy (Halliasos
et al., 2007; Nriagu, 2007). Newborns manifest zinc deficiency in hair loss, impaired speech,
increased infections, and neuropsychological problems (Halliasos et al., 2007).
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Chapter 5.1 – Metal Fume Fever Associated with Galvanized Welding
MFF (a flu-like illness) associated with galvanized welding is usually due to inhalation of
fumes generated from molten galvanized bronze or steel welding. An estimated 1500 – 2000
cases of MFF occur each year in the United States. In the welding process, zinc is melted,
producing zinc oxide fumes with particulates ranging from 0.1-1.0 µM in diameter, but
aggregation can form larger particle sizes (Wardhana & Datau, 2014).
As part of the inflammatory response to zinc fume inhalation, leukocytes form from
cytokine release in the lungs. Reactive oxygen species (ROS) increases, causing oxidative stress
(damage to cell structures) in the bronchiolar and alveolar regions of the lungs, generating more
free radical activity. Fever, coughing, wheezing, chest tightness, fatigue, chills, myalgia, cough,
dyspnea, leukocytosis with a left shift, thirst, metallic taste, and salivation are symptoms of MFF.
No specific treatment is advised for MFF. Flu-like symptoms may develop approximately 3
hours after exposure, with a high occurrence of respiratory symptoms or bronchial
responsiveness (Wardhana & Datau, 2014).
Pathological respiratory problems may arise as well. Peripheral broncho-alveolar lavage
(BAL) may be performed to determine if severe acute inflammation is present, via cell count of
polymorphonuclear (PMN) leukocytes. A hypothesis of pathogenesis is the release of
endogenous pyrogens from the leukocytes, as well as production of metal proteinases, or a group
of enzymes that can hydrolyze proteins. The resulting metal proteinases are composed of inhaled
particles and damaged pulmonary tissue, or antigens leading to the formation of allergenantibody complexes. These complexes cause the clinical symptoms although the mechanisms are
unclear for the symptoms. (Wardhana and Datau, 2014)
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ROS production also increases. Oxidative stress is caused from the deposit of zinc oxide
and oxidative stress, a pathway to ROS inducing a greater inflammatory response. (Wardhana
and Datau, 2014)
Eighteen hours after exposure, MFF symptoms peak, and are resolved within 1-2 days.
Typical treatments are anti-pyretics, analgesics, and oxygen therapy for hypoxia. Wearing masks
to prevent inhalation of fumes and particulates, and plenty of ventilation in work areas will help
prevent new cases of MFF (Wardhana & Datau, 2014).
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Chapter 5.2 – Diseases Related to Zinc Deficiencies
Zinc deficiency affects the epidermal, gastrointestinal, central, nervous, immune, skeletal,
and reproductive systems (Hambridge, 2000). Wilson’s disease and Alzheimer’s disease are both
age-related free copper toxicoses. Wilson’s disease pathology shows free plasma copper is toxic,
generating oxidative stress, free radicals, and degeneration of cortical neurons (Hoogenraad,
2011). Increases in free plasma zinc levels create MT expression and neuron damage,
inflammation, and oxidative stress. Copper toxicosis in age-related Alzheimer’s disease may be
ameliorated by zinc therapy (Avan & Hoogenraad, 2015).
Chelation therapy is not recommended for treatment of copper toxicosis and is deemed to
be dangerous (Hoogenraad, 2011). More research is needed to determine the benefits of zinc
supplements. Copper toxicosis therapy can inhibit zinc supplementation to the body within
homeostasis (Avan & Hoogenraad, 2015).
Zinc is present in hair, skin, nails, the immune system, metalloenzymes, alkaline
phosphatase, RNA, and DNA polymerase. Zinc deficiencies are noticeable in patients exhibiting
alopecia, perlèche, intractable vomiting, diarrhea, loss of appetite, apathy, and irritability. The
cutaneous signs of zinc deficiencies are lesions on the erythematous base crusting over, creating
a sharply marginated and lichenified form. Immune function is altered, permitting the growth of
yeast and bacteria thus creating impetigo, and paronychial infections (Haliasos et al., 2007). Zinc
metabolism attributes to phenotypic expression of the rare autosomal inherited disorder,
acrodermatitis enteropathica, characterized by dermatitis and alopecia (Moynahan, 1974;
(Hambridge, 2000).
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Diarrhea may cause zinc deficiency, as it is excreted from the body due in feces. Zinc
supplements in world meta-analysis of diarrheal incidences reduces the severity of loss of fluid
and zinc (Brown, 1998).
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Chapter 5.3 – Zinc Exposure
Water
Drinking water – 0.003 mg/L – 2.0 mg/L (2,000 ppb) (ATSDR, 2005)
Surface water – 0.002 mg/L – 1.2 mg/L (1,200 ppb) (ATSDR, 2005)
Soil concentrations
Mean – 60 mg/kg (60,000 ppb) (ATSDR, 2005)
Soil and sediment – < 5 mg/kg – 2,900 mg/kg (< 5,000 – 2,900,000 ppb) (ATSDR, 2005)
Dietary Intake – Ages
Recommended Daily Allowance
Infants 0 – 6 months – 2 mg/day (2,000 ppb) (NA, 2001)
Infants 7 – 12 months – 3 mg/day (3,000 ppb) (NA, 2001)
1 – 3 years – 3 mg/day (3,000 ppb) (NA, 2001)
4 – 8 years – 5 mg/day (5,000 ppb) (NA, 2001)
9 – 13 years males– 8 mg/day (8,000 ppb) (NA, 2001)
14 – 18 years males– 11 mg/day (11,000 ppb) (NA, 2001)
≥ 19 years males – 11 mg/day (11,000 ppb) (NA, 2001)
9 – 13 years females– 8 mg/day (8,000 ppb) (NA, 2001)
14 – 18 years females– 9 mg/day (9,000 ppb) (NA, 2001)
≥ 19 years females – 8 mg/day (8,000 ppb) (NA, 2001)
Pregnancy ≤ 18 – 12 mg/day (12,000 ppb) (NA, 2001)
Pregnancy 19 – 50 – 11 mg/day (11,000 ppb) (NA, 2001)
Lactation ≤ 18 – 13 mg/day (13,000 ppb) (NA, 2001)
Lactation 19 – 50 – 12 mg/day (12,000 ppb) (NA, 2001)
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Estimated Average Requirements
Infants 6 – 12 months – 2.5 mg/day (2,500 ppb) (NA, 2001)
1 – 3 years – 2.5 mg/day (2,500 ppb) (NA, 2001)
4 – 8 years – 4.0 mg/day (4,000 ppb) (NA, 2001)
9 – 13 years males – 7.0 mg/day (7,000 ppb) (NA, 2001)
14 – 18 years males – 8.5 mg/day (8,500 ppb) (NA, 2001)
≥ 19 years males – 9.4 mg/day (9,400 ppb) (NA, 2001)
9 – 13 years females – 7.0 mg/day (7,000 ppb) (NA, 2001)
14 – 18 years females – 7.3 mg/day (7,300 ppb) (NA, 2001)
≥ 19 years females – 6.8 mg/day (6,800 ppb) (NA, 2001)
Pregnancy 14 – 18 years – 10.5 mg/day (10,500 ppb) (NA, 2001)
Pregnancy 19 – 50 years – 9.5 mg/day (9,500 ppb) (NA, 2001)
Lactation 14 – 18 years – 10.9 mg/day (10,900 ppb) (NA, 2001)
Lactation 19 – 50 years – 10.4 mg/day (10,400 ppb) (NA, 2001)
Tolerable Upper Intake Levels
Infants 0 – 6 months – 4 mg/day (4,000 ppb) (NA, 2001)
Infants 6 – 12 months – 5 mg/day (5,000 ppb) (NA, 2001)
1 – 3 years – 7 mg/day (7,000 ppb) (NA, 2001)
4 – 8 years – 12 mg/day (12,000 ppb) (NA, 2001)
9 – 13 years – 23 mg/day (23,000 ppb) (NA, 2001)
14 – 18 years – 34 mg/day (34,000 ppb) (NA, 2001)
≥ 19 years – 40 mg/day (40,000 ppb) (NA, 2001)
Pregnancy 14 – 18 years – 34 mg/day (34,000 ppb) (NA, 2001)
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Pregnancy 19 – 50 years – 40 mg/day (40,000 ppb) (NA, 2001)
Lactation 14 – 18 years – 34 mg/day (34,000 ppb) (NA, 2001)
Lactation 19 – 50 years – 40 mg/day (40,000 ppb) (NA, 2001)
Standards and Guidelines
Minimum Risk Levels (MRL)
No Oral Acute duration was derived (ATSDR, 2005)
Oral intermediate duration – 0.3 mg/kg/day (300 ppb) (ATSDR, 2005)
Oral Chronic duration – 0.3 mg/kg/day (300 ppb) (ATSDR, 2005
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Chapter 6 – Materials and Methods
The crayfish samples were procured in the Atchafalaya Basin and anthropogenic pond
venues of South Central and South West Louisiana. The exoskeletons were removed and tail
tissues were put into acid rinsed containers then filled with pure water. Afterwards, the holding
containers were immediately put into a freezer for storage at 28ºF.
Samples were then transferred to the University of Louisiana at Lafayette engineering
department where testing procedures were implemented on the tail tissues. Samples were
defrosted in a laboratory refrigerator at approximately 40ºF.
The tail tissues were digested by microwave action. The samples were put individually
into acid rinsed glass tubules. Ten mL of nitric acid were added to the tubule, and the tubule was
filled to a designated fill line with pure water. Ten tissue and tubule samples were digested by
microwave action. The digestion time was 15 minutes for complete digestion. The samples were
then cooled for 20 minutes, and were ready for testing.
Testing commenced on each tissue sample from each tubule by Inductively Coupled
Plasma-Mass Spectrometer (ICP-MS). Afterwards, the 10 test conclusions were recorded on a
graph, interpreted, converted to numerical values in parts per billion, and micrograms per
kilogram. The test results are reported in micrograms (µg/kg) for the 50 samples tested for
arsenic, cadmium, copper, and zinc.
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Chapter 6.1 – Apparatus and Materials
The procedure for the preparation of solids and solid type materials for analysis by ICPMS employing the use of microwave assisted digestion is described herein.
Top loading balance capable of accurate weights to 0.001 g
Environmental Express Hot Block
Polypropylene digestion vessels: Environmental Express catalog # SC475
Reflux caps: Environmental Express catalog # SC506
Filtermate: Environmental Express catalog # SC 0401
Auto-pipettes or disposable glass pipettes
Plastic weighing boats
Boiling stones PTFE, 450 g bottle: Fisher Scientific catalog # 09-191-20
CEM MARS6 Microwave Reaction System
MARSXpress Plus vessels
Pure water (Elga Water Analyte-free): Evoqua Water Technologies LLC (Lowell, MA)
7700 Agilent ICP-MS Analyzer
Argon gas (high purity)
Helium gas (high purity)
Disposable polypropylene culture tubes (16 x 125 mm)
Computer system with Mass Hunter Workstation Software for ICP-MS, Version B.01.03
for data acquisition and manipulation
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Chapter 6.2 – Reagents and Standards
Concentrated nitric acid (trace metals grade): Fisher Scientific catalog #A509-212
Concentrated hydrochloric acid: Fox Scientific Instrapure catalog # H300-3
30% Hydrogen peroxide: Fisher Scientific catalog #H325-50
Metals Standard 7: Environmental Express catalog # ICQ500-7
ICP-MS: Calibration Standard Stock/ICP-MS Spike
Standard: Place the amounts of each parent (designated in the table below) into a 500 mL
volumetric flask. Add 20 mL HNO3. Bring to volume using Elga water.
Table 1 – Reagents and Standards
Amount of
Parent
Concentration
Parent
1.25 mL
2.5 ppm
Aluminum (1000 ppm)
1.25 mL
2.5 ppm
Antimony (1000 ppm)
1.25 mL
2.5 ppm
Arsenic (1000 ppm)
1.25 mL
2.5 ppm
Beryllium (1000 ppm)
1.25 mL
2.5 ppm
Boron (1000 ppm)
1.25 mL
2.5 ppm
Cadmium (1000 ppm)
1.25
mL
2.5 ppm
Chromium (1000 ppm)
1.25 mL
2.5 ppm
Cobalt (1000 ppm)
1.25 mL
2.5 ppm
Copper (1000 ppm)
1.25 mL
2.5 ppm
Iron (1000 ppm)
1.25 mL
2.5 ppm
Lead (1000 ppm)
1.25 mL
2.5 ppm
Lithium (1000 ppm)
1.25 mL
2.5 ppm
Manganese (1000 ppm)
1.25
mL
2.5 ppm
Molybdenum (1000 ppm)
1.25 mL
2.5 ppm
Nickel (1000 ppm)
1.25 mL
2.5 ppm
Selenium (1000 ppm)
1.25 mL
2.5 ppm
Strontium (1000 ppm)
1.25 mL
2.5 ppm
Thallium (1000 ppm)
1.25 mL
2.5 ppm
Tin (1000 ppm)
1.25 mL
2.5 ppm
Zinc (1000 ppm)

Use the above solution to make the MS/MSD by spiking with 1.0 mL of each standard to
a final volume of 50 mL.
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Chapter 6.3 – Digestion Procedure
Remove the crayfish tail from the sample jar into a plastic weighing boat. For each
digestion procedure, weigh out whole crayfish tail or minimum of 1-2 grams of sample (weigh to
the nearest 0.001 g) into a labeled polypropylene digestion vessel. The method used for fish
parts, crayfish parts, or other biological samples is found under “Classic Methods” and labeled
“Fish Digestion 3.”
Power level of MARS6: set at 1500 watts
Ramp time: 15 minutes
Hold Time: 15 minutes
Temperature is set at 200ºC (not to exceed 260ºC)
Once digestion is complete and the samples have cooled, the sample is brought to a final volume
of 50 mL with Elga water and then analyzed.
If the data must be reported based upon dry weight, determine the moisture content by the
following: weigh out about 0.5 g of tissue into an aluminum pan (tare the weight of the pan
before adding tissue). Record the total weight to 0.0001 g. Dry the sample in an oven at 103 –
105°C until weight loss is stable. Adjust the weight of sample extracted, for the moisture content
by using the following formula:
Dry Wt. = (Wtd - Wtt) x

Wts

(Wtw - Wtt)
where Dry Wt. is weight as dry tissue, Wtd is weight of dried pan and tissue, Wt t is tare weight
of aluminum pan, Wts is weight of wet tissue to be extracted, and Wt w is the total weight of pan
and wet tissue. All weights are in grams (g).

73

Chapter 6.4 – Quality Assurance/Quality Control (QAQC) for Digestion Procedure
A LCS, a method blank, a matrix spike, and a matrix spike duplicate are prepared for
each batch of 20 samples.
Tissue Quality Assurance/Quality Control (QAQC) Samples:
LCS: Weigh out 1.0 g of Teflon boiling chips. Water and acids are added to the vessel, and
spikes are chosen based on analyses required. Note: Add spiking solutions before acids (HNO3
and HCl).
a. For ICP-MS: 1.0 mL of each solution in Chapter 6.2
b. Proceed with digestion as explained in Chapter 6.3
Matrix spike and matrix spike duplicates: are made by adding the desired spiking solution to
the matrix sample as described above, and treating the samples as described in Chapter 6.2. Note:
Add spiking solutions before acids are added.
Method blank: For soil samples should consist of 1.0 g of Teflon boiling chips and the acids
HNO3 and HCl, as well as the peroxide used in the digestion procedure.
The acceptability criteria for soils is method specified 75 – 125% recovery for LCS,
MS/MSD.
In the event of MS/MSD failure, a post digestion spike (PDS) of the parent sample must
be prepared and analyzed. As MS/MSD failure is common for metals analyses, it is
recommended the analyst prepare a PDS along with the regular MS/MSD as part of the batch
QAQC.
Preparation of the PDS: Remove an aliquot of the un-spiked parent sample digestate. Spike the
digestate with the same amount and concentration of the MS/MSD spiking solution. If the
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recovery of the PDS is within 85-115%, matrix effect should be suspected, and it becomes clear
that the quantitation of the extract at the instrument was accurate.
If both the MS/MSD and PDS fail, matrix effects are confirmed.
If the analyte concentration is ≥ 10 times the reporting limit, a dilution test must be
conducted. To conduct the dilution test, prepare a 1 to 5 dilution of the parent sample digestate.
If the analysis of the 1 to 5 dilution does not agree within ±10% of the original determination, a
chemical or physical interference should be suspected.
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Chapter 6.5 – ICP-MS Analysis Procedure
ICP-MS Working Calibration Standards: Place the amount of the parent standard solution
from Chapter 6.2 (designated in the table below) into a 50mL digestion tube. Add 2 mL of
HNO3. Bring to volume using Elga water. Repeat procedure for each standard. There 6
standards.
Table 2 – ICP-MS Calibration Standards (Working)
Amount of
Concentration at
6 Standards
Parent
Instrument in ppb
ICP-MS Calibration Standard Stock plus
1.250 mL each
625.00
ICP-MS Silver Calibration Standard Stock
ICP-MS Calibration Standard Stock plus
5.000 mL each
250.00
ICP-MS Silver Calibration Standard Stock
ICP-MS Calibration Standard Stock plus
2.000 mL each
100.00
ICP-MS Silver Calibration Standard Stock
4.000 mL
20.00
250 ppb from above
0.400 mL
2.00
250 ppb from above
0.625 mL
0.25
20 ppb from above

Internal Standard Stock: Place 0.5 mL of each of the analytes below into Elga water. Add 20
mL of HNO3 and bring to a final volume of 500 mL.
Table 3 – Analytes
Analyte
Bismuth
Holmium
Indium
Rhodium
Scandium
Terbium
Yttrium

Catalog
Number

Vendor

HP10006-1
HP10023-1
HP10024-1
HP10044-2
HP10048-1
HP10057-1
HP10067-1

Environmental Express
Environmental Express
Environmental Express
Environmental Express
Environmental Express
Environmental Express
Environmental Express

Original
Concentration
Final
Purchased
Concentration
Standard
1000 mg/L
1.0 mg/L
1000 mg/L
1.0 mg/L
1000 mg/L
1.0 mg/L
1000 mg/L
1.0 mg/L
1000 mg/L
1.0 mg/L
1000 mg/L
1.0 mg/L
1000 mg/L
1.0 mg/L

Internal Standard Working Solution: Place 25 mL of Internal Standard Stock with 10 mL
HNO3 and bring to 250 mL with Elga water.
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Table 4 – ICP-MS Agilent Stock Standard Tuning Solutions
Analyte
Concentration
1 mg/L
Cesium
1 mg/L
Cobalt
1 mg/L
Lithium
1 mg/L
Thallium
1 mg/L
Yttrium
Table 5 – Agilent 7500 Series PA Tuning Stock Standard Solutions 1 and 2
PA Solution 1
PA Solution 2
Analyte
ConcentraAnalyte
ConcentraAnalyte
Concentration
tion
tion
20.0 mg/L
5 mg/L
10 mg/L
Arsenic
Bismuth
Germanium
20.0 mg/L
5 mg/L
10 mg/L
Beryllium
Cobalt
Molybdenum
20.0 mg/L
5 mg/L
10 mg/L
Cadmium
Chromium
Ruthenium
20.0 mg/L
5 mg/L
10 mg/L
Zinc
Copper
Antimony
10.0 mg/L
5 mg/L
10 mg/L
Magnesium
Indium
Tin
10.0 mg/L
5 mg/L
5 mg/L
Nickel
Lithium
Iridium
10.0 mg/L
5 mg/L
5 mg/L
Lead
Lutetium
Titanium
5.0 mg/L
5 mg/L
10 mg/L
Aluminum
Manganese
Palladium
5.0 mg/L
5 mg/L
Barium
Sodium
5.0 mg/L
5 mg/L
Strontium
Scandium
5.0 mg/L
5 mg/L
Thallium
Thorium
5.0 mg/L
5 mg/L
Uranium
Titanium
2.5 mg/L
5 mg/L
Yttrium
Vanadium
2.5 mg/L
Ytterbium
Table 6 – ICP-MS 200.8 Stock Parent Tuning Solution
Analyte
Concentration
1,000 mg/L
Beryllium
1,000 mg/L
Cobalt
1,000 mg/L
Indium
1,000 mg/L
Lead
1,000 mg/L
Magnesium

Agilent Working Tune Standard: The standard is prepared fresh as needed from the purchased
standard described in Table 4. 50 µL of the stock standard and 20 mL HNO3 is brought to a final
volume of 500 mL with Elga water in a class A volumetric.
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Agilent 7500 Series PA Working Tune Standard: The standard is prepared fresh as needed
from the purchased standard described in Table 5. Standard PA 1 PA 2 (6.66 mL each) and 20
mL HNO3 are brought to a final volume of 500 mL in a class A volumetric with Elga water.
ICP-MS 200.8 Tune-Stability Working Solution: The standard is prepared from a stock parent
solution described in Table 6 and from the ICP-MS Agilent stock standard tuning solution. 0.5
mL of each standard with 20 mL HNO3 is brought to a final volume of 500 mL in a class A
volumetric with Elga water.
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Chapter 6.6 – Quality Assurance/Quality Control (QAQC) for ICP-MS Procedure
Each analytical batch requires the preparation and analysis of a method blank, LCS, MS,
and MSD. Method blank for water samples consists of Elga water containing 4% concentrated
nitric acid. Method blank for soil samples consists of Elga water containing 10% nitric acid.
Calibration blank is prepared using 48 mL Elga water and 2 mL of concentrated nitric acid to a
final volume of 50 mL.
In the case of MS/MSD failure, a post-digestion spike is prepared and analyzed. A
MS/MSD failure is common for metals analyses, and it is recommended the analyst prepare a
post-digestion spike along with the regular MS and MSD as part of the batch QAQC.
Preparation of the Post Digestion Spike (PDS): Remove an aliquot of the un-spiked parent
sample digestate. Spike the digestate with the same amount and concentration of the MS/MSD
spiking solution. If the recovery of the PDS is greater than +15% of the expected value, matrix
effect should be suspected. If the recovery of the PDS is within +15%, the quantitation of the
extract at the instrument was accurate.
If both the MS/MSD and PDS fail, matrix effects are confirmed. If the analyte
concentration is sufficiently high (minimally a factor of 10 above the lower limit of quantitation
after dilution), a dilution test must be conducted.
To conduct the dilution test, prepare a 1 to 5 dilution of the parent sample digestate.
If the analysis of the 1 to 5 dilution does not agree within +10% of the original determination, a
chemical or physical interference should be suspected.
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Table 7 – Summary, Required Quality Control, Frequency, and Acceptable Limits
Procedure
Frequency
Acceptable Limits
Daily after the initial calibration
Low Level ICV: 70 – 130%
Low Level ICV: same source as Cal.
Mid Level ICV: % Rec.
Stds.; concentration at Quantitation Limit +10% of T.V. as per Method
ICV
of water
200.8
Mid Level ICV: 2nd source
Mid Level CCV: After every 10
Mid Level CCV: % Rec.
samples and at the end of the run. Second +10% of t.V. as per Methods
source
200.8 and 6020A
Low Level CCV: Concentration at the
Low Level CCV: 70 – 130%
CCV
Quantitation Limit of water. Analyzed at
the beginning and end of batch at a
minimum (same source as calibration
standards)
Run as part of the calibration curve and
Analytes must be less than
Calibration
also every 10 samples
Reporting Limit
Blank
One
per
sample
batch;
used
to
identify
Analytes must be less than
Method Blank
possible contamination
Reporting Limit
At least one LCS per batch of samples;
% Rec. 85 – 115 (water) as per
LCS
two should be used to track precision if a Method 200.8
MS/MSD pair is not used.
Second Source
One per batch of 20 samples
%Rec. 75 – 125% as per
MS
6020A
One
per
batch
of
20
samples
except
RPD 20% as per 6020A
MSD
TCLP
Analyzed when BOTH MS and MSD fail %Rec. 85 – 115; If failure
Post Digestion
occurs, analyze a 1/5 dilution
Spike (PDS)
of parent digestate
Analyze a 1/5 dilution of parent digestate If 1/5 digestate results are
in the event of PDS failure IF the parent
within +10% of UNDILUTED
sample contains analyte concentration at
digestate, matrix effect ruled
Dilution Test
least 10X the limit of quantitation
out; if > +10% difference,
matrix effects confirmed
Analyzed at the beginning of each sample 75 – 125% of T.V.
Interference
Check Sample run
Analyzed annually to verify the reporting 50 – 150%
Lower Limit of limit.
Spike a QAQC at the reporting limit of
Quantitation
Check Sample water. Prep and analyze as a regular
sample using the same source as
(LLQC)
calibration standards.
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Note to Table 7: Acceptance criteria for water are method defined: LCS 85 – 115% recovery;
MS/MSD 75 – 125% Recovery; 20% RPD. The acceptability criteria for soil are method
specified: 80 – 120% recovery for LCS; 75 – 125% recovery MS/MSD. The criteria used for
wipes and filters are the same for soils.
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Chapter 6.7 – Materials and Methods References
SW-846: Method 6020A, Revision 1, February 2007
EPA Methods for Chemical Analysis of Water and Wastewater Method 200.8, Revision 5.4
(1994), EMMC Version

82

Chapter 7 – Test Results and Statistics
Chapter 7.1 – Arsenic Test Results and Statistics – Tail with Intestine

Sample Name
ATCH-B-1
ATCH-B-2
ATCH-B-3
ATCH-B-4
ATCH-B-5
ATCH-B-6
ATCH-B-7
ATCH-B-8
ATCH-B-9
ATCH-B-10
ATCH Extra
ATCH Extra & 11 TS
CHI-1
CHI-2
CHI-3
CHI-4
CHI-5
CHI-6
CHI-7
CHI-8
CHI-9
CHI-10
DOM-1-1
DOM-1-2
DOM-1-3
DOM-1-4
DOM-1-5
DOM-1-6
DOM-1-7
DOM-1-8
DOM-1-9
DOM-1-10
DOM-2-1
DOM-2-2
DOM-2-3
DOM-2-4
DOM-2-5
DOM-2-6

Table 8 – Tail with Intestine
Result
Detection
Reference
(µg/kg)
Limit
Limit
28.30
1.730
2.89
85.30
1.300
2.17
28.30
1.110
1.84
48.90
1.260
2.11
29.30
1.120
1.86
52.00
1.500
2.49
27.80
0.976
1.63
43.70
1.590
2.66
50.00
1.460
2.43
17.30
1.110
1.85
29.50
1.900
3.17
23.90
1.610
2.69
216.00
14.600
24.30
84.10
14.000
23.30
74.50
15.700
26.20
151.00
16.300
27.20
93.00
12.100
20.10
204.00
13.400
22.30
241.00
18.300
30.50
188.00
14.800
24.70
90.90
15.800
26.40
96.60
11.800
19.70
191.00
1.230
2.05
<2.13
1.280
2.13
80.70
8.990
15.00
72.30
10.900
18.20
104.00
9.960
16.60
93.70
7.360
12.30
66.30
9.760
16.30
89.70
9.920
16.50
75.10
12.600
21.00
74.40
11.000
18.40
104.00
15.700
26.20
73.20
13.500
22.50
90.80
17.200
28.70
66.10
11.100
18.50
74.30
13.500
22.50
53.60
13.700
22.80
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Dilution
1
1
1
1
1
1
1
1
1
1
1
1
10
10
10
10
10
10
10
10
10
10
1
1
10
10
10
10
10
10
10
10
10
10
10
10
10
10

Sample Name
DOM-2-7
DOM-2-8
DOM-2-9
DOM-2-10
FRE-1
FRE-2
FRE-3
FRE-4
FRE-5
FRE-6
FRE-7
FRE-8
FRE-9
FRE-10
FRE-Extra

(Table 8 cont.)
Result
Detection
(µg/kg)
Limit
92.40
14.300
84.70
20.200
72.30
18.300
98.10
15.200
72.10
1.490
102.00
1.050
83.30
1.510
69.40
1.210
79.60
0.873
58.50
0.949
107.00
0.986
84.60
1.230
90.50
1.100
94.30
1.250
83.70
1.370

Reference
Limit
23.80
33.60
30.50
25.30
2.49
1.75
2.52
2.02
1.45
1.58
1.64
2.05
1.84
2.09
2.28

Dilution
10
10
10
10
1
1
1
1
1
1
1
1
1
1
1

The Means Procedure
This provides a data summary computing descriptive statistics for the variables across
groups of observations (ATCH-B, CHI, DOM-1, DOM-2, FRE, and Intestine). It provides the
number of observations, the mean, standard deviation, minimum value, and maximum values for
all the observations and between groups.
Welch’s ANOVA Procedure
The analysis of variance procedure (ANOVA) performs analysis of variance, which
measures the variation of the response variable across the groups. Caution: ANOVA procedure
in SAS is used for balanced data. Since this data is unequal across test groups, the validity of the
results are questionable.
The GLM Procedure
The generalized linear model procedure (GLM) in SAS uses least squares to fit linear
models. Since the dependent variables used here are classification groups, the analysis becomes
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analysis of variance. This type of analysis of variance can handle unbalanced data. This output
gives the same results as the ANOVA procedure, but also gives type I and type II sums of
squares. These sums of squares deal with the model being assumed and since there is only one
factor at four levels, both types of sums of squares is equal to the model sum of squares. The
GLM procedure also tests for the model assumption of homogeneity. Homogeneity is the
equality of variances. The GLM Procedure uses Levene’s Test to validate homogeneity.
The Univariate Procedure
The univariate procedure provides a Q-Q Plot of the residuals verses the quantiles of the
data observations. This is necessary to validate the ANOVA model. Normality of the
observations is an important model assumption and validated by a Q-Q Plot.
T Tests (LSD) for Result
Fisher’s least significant difference test (LSD) compares the mean of one group to the
means of another at a certain significance level using the t distribution to determine if the
responses from two different groups differ significantly.
Tukey’s Studentized Range (HSD) Test for Results
Tukey’s honest significant difference (HSD) compares the means of one group to the
means of another using a studentized range distribution. It is mainly used when there are unequal
sample sizes.
Conclusions from Data
With 53 observations, the mean response variable across all groups is 84.66 with a
standard deviation of 48.87. The minimum value is 2.13 and the maximum is 241. The ATCH-B
group has 12 observations with a mean of 38.69, a standard deviation of 18.56, a minimum value
of 17.3, and a maximum value of 85.30. The CHI group has 10 observations with a mean of
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149.91, a standard deviation of 63.48, a minimum value of 74.5 and a maximum value of 241.00.
The DOM-1 group has 10 observations with a mean of 84.93, a standard deviation of 46.31, a
minimum value of 2.13, and a maximum value of 191.00. The DOM-2 group has 10
observations with a mean of 80.95, a standard deviation of 15.69, a minimum value of 53.60, and
a maximum value of 104.00. The FRE group has 11 observations with a mean of 84.09, a
standard deviation of 14.24, a minimum value of 58.50, and a maximum value of 107.00. The
intestine group has 5 observations with a mean of 340.26, a standard deviation of 250.26, a
minimum value of 54.30, and a maximum value of 668.00.
The means of five groups (ATCH-B, CHI, DOM-1, DOM-2, and FRE) were tested using
ANOVA to see if the groups were significantly different. The model used is assumed to be
𝑦𝑖𝑗 = 𝜇 + 𝜏𝑖 + 𝜖𝑖𝑗 , where 𝑦𝑖𝑗 is an individual observation, 𝜇 is the overall mean, 𝜏𝑖 is treatment
effect, and 𝜖𝑖𝑗 is the random error. ANOVA tests the equality of treatment means. Since the p
value is less than 0.0001, this suggests that one or more of the groups are significantly different.
Since ANOVA is valid for equal sample sizes, GLM performed to account for unequal sample
sizes. The p value is still less than 0.0001, which further validates that the groups significantly
differ. This is also easily seen on the box plot. The R2 value in the GLM is 0.488, meaning 48.8%
of the response variables can be explained or predicted by the groups.
Comparisons of one group to another were made by t tests and Tukey’s studentized range
tests. It was found that CHI and ATCH-B groups were significantly different than the other
groups. The Tukey’s studentized range concludes that ATCH-B is only significantly different
from CHI, DOM-1, and FRE, not DOM-2. This difference in conclusions is due to the unequal
sample sizes.
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Model assumptions must be valid for these results to hold true. The two assumptions are
homogeneity and normality of the data. Homogeneity means equal variances across all groups
and is determined by Levene’s test which compares the variances of each group. Since the p
value of this test is below the significance value, the null hypothesis of the variances being equal
can be rejected. Hence, the variances are not the same and homogeneity cannot be assumed. This
can be seen in the box plots very easily. It appears that the variance of CHI differs significantly
compared to the other groups. Caution is recommended when forming conclusions on CHI
group. A quantile-quantile plot is used to check normality. The Q-Q plot of the residuals appears
linear, so normality of the data set holds.
In conclusion, ATCH-B was significantly lower than the rest of the groups, with a mean
of 38.69 while CHI was significantly higher with a mean of 143.91. The variance of CHI was
also much higher than any of the tests groups which could have contributed to the failing of
Levene’s test. Responses from groups DOM-1, DOM-2, and FRE did not significantly differ
from each other.
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Chapter 7.2 – Arsenic Test Results and Statistics – Intestine

Sample Name
ATCH-B
CHI
DOM-1
DOM-2
FRE

Table 9 – Intestine
Result
Detection
(µg/kg)
Limit
54.3
24.90
668.0
14.90
135.0
49.30
476.0
3.74
368.0
20.20

Reference
Limit
41.50
24.80
82.20
6.24
33.60

Dilution
1
1
1
1
1

The T Test Procedure
This procedure performs t tests and calculates confidence limits (CI) for one sample,
paired observations, or two independent samples.
The Means Procedure
This provides a data summary computing descriptive statistics for the variables across
groups of observations (ATCH-B, CHI, DOM-1, DOM-2, FRE, and Intestine). It provides the
number of observations, the mean, standard deviation, minimum value, and maximum values for
all the observations and between groups.
Arsenic Statistical Analysis Results
Intestine type N group was composed of 53 samples with a mean of 84.67, a standard
deviation of 48.87, a standard error of 6.71, a minimum value of 2.13, and a maximum value of
241.00. Ninety-five percent of the samples were located between 71.19 and 98.14. The intestine
type Y group was composed of five samples with a mean of 340.3, a standard deviation of 250.3,
a standard error of 111.9, a minimum value of 54.30, and a maximum value of 668.00. Ninetyfive percent of intestine type Y’s samples were located between 29.53 and 651.0. The groups’
difference had an average of -255.6, a standard deviation of 81.80, and a standard error of
38.2691.
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For testing, if the means are significantly different, two assumptions must be satisfied:
the variances of the two groups must be equal and the data must follow a normal distribution. A
pooled t test was performed to test the difference of the means. A pooled t test assumes the
variances are equal, all the samples are independent, and each sample is sampled from a
population that is approximately normally distributed. The p value for this test is less than
0.0001, which is less than the significance level of 0.05. This suggests the means of the two
groups are significantly different, having a higher arsenic concentration in the Y group than the
N group. The Satterthwaite procedure is a way of testing means with unequal variances. The p
value for this test was computed as 0.0843 which is greater than the significance level of 0.05.
The Satterthwaite holds stronger inferences if the variances are unequal.
An f-test is used to test for equality of variances, but it is extremely sensitive to normality
assumptions. The p value for this test is less than 0.0001, so it can be concluded that the
variances are not equal. This concludes that the Satterthwaite holds stronger conclusions that the
two tail groups do not significantly differ.
The distributions for the two groups were checked by plotting and fitting normal
distributions and a composing a Q-Q plot. The results of the distribution for the N group do not
appear normal. Deviations from the Q-Q plot exist and the distribution appears to be skewed.
This could be fixed by transforming the data or other tests could be performed for more robust
inferences for a skewed distribution. The distribution for the Y tail group also deviates from
normality, which could be fixed by having a higher sample size. Since both groups depart from
normality, the f-test does not hold as strong, and the Satterthwaite may not offer a certain
conclusion. From initial observations of the difference in means and the initial results of the
pooled t test, further investigations on this subject should be made.
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Chapter 7.3 – Arsenic Statistical Report
Arsenic concentration was analyzed in 53 tail samples. The sample mean, sample
standard deviation, the minimum, and the maximum values are reported in the table below.
Table 10 – Analysis Variable Results – Total Samples
N
Mean
Std Dev
Minimum
Maximum
53
84.67
48.87
2.13
241.00

The table below summarizes the key statistics for arsenic in the tails with intestine by the
site.
Table 11 – Analysis Variable Results – Tail with Intestine
Sample
Name
ATCH-B
CHI
DOM-1
DOM-2
FRE

N

Mean

Std Dev

Minimum

Maximum

12
10
10
10
11

38.69
143.91
84.93
80.95
84.09

18.56
63.48
46.31
15.69
14.24

17.30
74.50
2.13
53.60
58.50

85.30
241.00
191.00
104.00
107.00

The table below summarizes the key statistics for the intestine.

Y
5

Table 12 – Analysis Variable Results – Intestine
Mean
Std Dev
Minimum
Maximum
340.26
250.26
54.30
668.00

Statistical Comparison of tails and Intestines: Note that there are 53 readings for the tails,
whereas there are only five for the intestine. In the plots, the variable gut type is coded as Y for
the arsenic in intestines and as N for the arsenic in tails. The figure first summarizes the
statistical distribution for these two populations. Note that graphically the fitted normal
distribution seems normal for the tails, but not so for the intestines. With only five observations
from the intestines, it is quite difficult to form a convincing conclusion. The figure below also
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depicts boxplots for the tails and intestines. The boxplot for tails depicts the potential outlier
arsenic observations. This is studied further via GLM.
Figure 2 – Distribution of Result – Tails and Intestines
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A QQ plot shows mild departure from normality. Note that the sample size of tails is
moderately large and the central limit theorem will ensure the normality requirement for the
statistical tests provided below.
Figure 3 – Q-Q Plots of Result
Q-Q Plots of Result
250

Y

N
600

200

400

Result

Result

150

100

200

50

0
0
-2

-1

1

0

-1.0

2

-0.5

0.0

0.5

1.0

Quantile

Quantile

The comparisons of the means for the arsenic in the crayfish tails versus intestines is
carried out next using the t test. The mean arsenic in the tails is about 255.6 µg/kg smaller than
the mean arsenic in the intestine.

Type
Tails with
Intestine
Intestine
Difference

Table 13 – T Test
Std Dev
Std Err

N

Mean

53

84.67

48.87

5

340.30
-255.60

250.30
81.80
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Minimum

Maximum

6.71

2.13

241.00

111.90
38.27

54.30

668.00

The table below provides 95% confidence limits (CL) for the mean arsenic contents in
the tails and intestines. The table also provides a 95% confidence limits for the standard
deviations. The mean differences are pooled, which assumes equal variances for tails and
intestines, and the Satterthwaite are provided in the table below. The Satterthwaite test uses the
Satterthwaite approximation for degrees of freedom. The confidence limits for the standard
deviations are of the equal-tailed variety. Note that the sample standard deviation for the arsenic
in the tails is 48.87 µg/kg, whereas for intestines it is 250.3 µg/kg. This difference in standard
deviations (or variances) is tested via a folded F-Test and the test concludes that the variances are
unequal with p value of <0.0001.

Type
Tails
Intestine
Difference
Difference

Method

Pooled
Satterthwaite

Table 14 – 95% Confidence Limits
Mean
95% CL Mean
Std Dev
84.67
71.19
98.14
48.87
340.30
29.53
651.00
250.30
-255.60 -332.30 -178.90
81.80
-255.60 -566.00 54.82

95% CL Std Dev
41.02
60.47
149.90 719.10
69.06
100.30

The tables below provide the p values for the difference in the mean arsenic contents
between tails and intestines under both equal and unequal variances. Assuming the variances are
equal, the p value of the difference is highly significant (p value <0.0001); assuming that the
variances are unequal, the p value is 0.0843.

Method
Pooled
Satterthwaite

Method
Folded F

Table 15 – P values
Variances
DF
t Value
Equal
56.00
-6.68
Unequal
4.03
-2.28

Pr > |t|
<.0001
0.0843

Table 16 – P-value – Equality of Variances
Num DF
Den DF
F Value
4
52
26.22

Pr > F
<.0001
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Statistical Comparison of Tails: We have collected 53 observations on the arsenic contents in
the tails from five sites. The figure below shows the boxplots of arsenic content by site.
Figure
4 – Distribution
Results – Tails
Distribution
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A quick visual inspection shows that ATCH-B site has the lowest arsenic in the tails, and
CHI the highest. The other three sites, DOM-1, DOM-2, and FRE are quite similar in arsenic
contents in the tails. Next, via a GLM, an unbalanced ANOVA model is fitted.
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First, we test the assumption of the equality of the variances by Levene’s Test. Note that
the Levene’s Test rejects the assumption of homogeneity of variance with a p value of <0.0001.
Table 17 – Levene’s Test for Homogeneity of Result Variance
ANOVA of Absolute Deviations from Group Means
Sum of
Mean
Source
DF
F Value
Pr > F
Squares
Square
4
14730.7
3682.7
9.29
<.0001
Sample Name
48
19030.6
396.5
Error

Since the assumption of homogeneity of variance is suspect, we report the results of the
ANOVA test which is robust to violation of the assumption of equal variances for one-way
models.
Table 18 – Welch’s ANOVA for Result
Source
DF
F Value
Pr > F
4.0000
14.56
<.0001
Sample Name
22.6836
Error

The ANOVA test concludes that there is a statistically significant difference in the mean
arsenic in tails from the five sites with a p value of <0.0001.
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The QQ plot of the residuals plotted below does not show large departures from the
normality.
Figure 5 – Q-Q Plot for Resid
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Tukey's Studentized Range (HSD) Test (Post Hoc): The post hoc tests are designed for further
investigation into the situations when the F-Test is significant and the researcher is interested in
which means are significantly different from each other. Tukey’s studentized range test corrects
for multiple tests so that a correct Type I experiment error rate is maintained, even though
multiple tests or comparisons are computed.
The tables below summarize the Tukey’s test and statistically significant differences at
the 5% level are indicated below.
Table 19 – Turkey’s Studentized Range (HSD) Test
0.05000
Alpha
48.00000
Error Degrees of Freedom
1324.95200
Error Mean Square
4.00812
Critical Value of Studentized Range
Table 20 – Turkey’s Studentized Range (HSD) Test
Comparisons significant at the 0.05 level are indicated by ***
Difference
Sample Name
Simultaneous 95%
Between
Comparison
Confidence Limits
Means
58.98
12.84
105.11
CHI – DOM-1
***
59.82
14.74
104.89
CHI – FRE
***
62.96
16.82
109.10
CHI – DOM-2
***
105.22
61.05
149.39
CHI – ATCH-B
***
-58.98
-105.11
-12.84
DOM-1 – CHI
***
0.84
-44.23
45.92
DOM-1 – FRE
3.98
-42.15
50.12
DOM-1 – DOM-2
46.24
2.07
90.41
DOM-1 – ATCH-B
***
-59.82
-104.89
-14.74
FRE – CHI
***
-0.84
-45.92
44.23
FRE – DOM-1
3.14
-41.93
48.22
FRE – DOM-2
45.40
2.34
88.46
FRE – ATCH-B
***
-62.96
-109.10
-16.82
DOM-2 – CHI
***
-3.98
-50.12
42.15
DOM-2 – DOM-1
-3.14
-48.22
41.93
DOM-2 – FRE
42.26
-1.91
86.43
DOM-2 – ATCH-B
-105.22
-149.39
-61.05
ATCH-B – CHI
***
-46.24
-90.41
-2.07
ATCH-B – DOM-1
***
-45.40
-88.46
-2.34
ATCH-B – FRE
***
-42.26
-86.43
1.91
ATCH-B – DOM-2
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Summary and Limitations: Due to small sample size for intestines and the CHI site showing
some unusually high levels of arsenic in the tails, the difference between tails and intestines is
mildly statistically significant.
There is a strong statistical difference between the five sites. The arsenic content in
DOM-1, DOM-2, and FRE is not statistically significant. CHI is significantly larger than these
three sites. ATCH-B has the lowest arsenic content.
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Chapter 7.4 – Cadmium Test Results and Statistics – Tail with Intestine

Sample Name
ATCH-B-1
ATCH-B-2
ATCH-B-3
ATCH-B-4
ATCH-B-5
ATCH-B-6
ATCH-B-7
ATCH-B-8
ATCH-B-9
ATCH-B-10
ATCH Extra
ATCH Extra & 11 TS
CHI-1
CHI-2
CHI-3
CHI-4
CHI-5
CHI-6
CHI-7
CHI-8
CHI-9
CHI-10
DOM-1-1
DOM-1-2
DOM-1-3
DOM-1-4
DOM-1-5
DOM-1-6
DOM-1-7
DOM-1-8
DOM-1-9
DOM-1-10
DOM-2-1
DOM-2-2
DOM-2-3
DOM-2-4
DOM-2-5
DOM-2-6
DOM-2-7
DOM-2-8

Table 21 – Tail with Intestine
Result
Detection
Reference
(µg/kg)
Limit
Limit
<2.89
1.730
2.89
<2.17
1.300
2.17
<1.84
1.110
1.84
<2.11
1.260
2.11
<1.86
1.120
1.86
<2.49
1.500
2.49
<1.63
0.976
1.63
<2.66
1.590
2.66
<2.43
1.460
2.43
<1.85
1.110
1.85
<31.70
19.000
31.70
<2.69
1.610
2.69
<24.30
14.600
24.30
<23.30
14.000
23.30
<26.20
15.700
26.20
<27.20
16.300
27.20
<20.10
12.100
20.10
<22.30
13.400
22.30
<30.50
18.300
30.50
<24.70
14.800
24.70
<26.40
15.800
26.40
<19.70
11.800
19.70
<2.05
1.230
2.05
<2.13
1.280
2.13
<15.00
8.990
15.00
<18.20
10.900
18.20
<16.60
9.960
16.60
<12.30
7.360
12.30
<16.30
9.760
16.30
<16.50
9.920
16.50
<21.00
12.600
21.00
<18.40
11.000
18.40
<26.20
15.700
26.20
<22.50
13.500
22.50
<28.70
17.200
28.70
<18.50
11.100
18.50
<22.50
13.500
22.50
<22.80
13.700
22.80
<23.80
14.300
23.80
<33.60
20.200
33.60
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Dilution
1
1
1
1
1
1
1
1
1
1
10
1
10
10
10
10
10
10
10
10
10
10
1
1
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

Sample Name
DOM-2-9
DOM-2-10
FRE-1
FRE-2
FRE-3
FRE-4
FRE-5
FRE-6
FRE-7
FRE-8
FRE-9
FRE-10
FRE-Extra

(Table 21 cont.)
Result
Detection
(µg/kg)
Limit
<30.50
18.300
<25.30
15.200
<2.49
1.490
<1.75
1.050
<2.52
1.510
<2.02
1.210
<1.45
0.873
<1.58
0.949
<1.64
0.986
<2.05
1.230
<1.84
1.100
<2.09
1.250
<2.28
1.370

Reference
Limit
30.50
25.30
2.49
1.75
2.52
2.02
1.45
1.58
1.64
2.05
1.84
2.09
2.28

Dilution
10
10
1
1
1
1
1
1
1
1
1
1
1

The Means Procedure
With 53 observations, there is a mean of 4.05, a standard deviation of 3.35, a minimum
value of 0.44, and a maximum value of 10.10. The group ATCH-B has 12 observations with a
mean of 1.41, a standard deviation of 2.55, a minimum value of 0.49, and a maximum value of
9.50. The group CHI has 10 observations with a mean of 7.34, a standard deviation of 0.99, a
minimum value of 5.90, and a maximum value of 9.15. The group DOM-1 includes 10
observations, with a mean of 4.15, a standard deviation of 1.98, a minimum value of 0.62, and a
maximum value of 6.30. The group DOM-2 has 10 observations with a mean of 7.64, a standard
deviation of 1.34, a minimum value of 5.55, and a maximum value of 10.10. The group FRE has
11 observations with a mean of 0.59, a standard deviation of 0.11, a minimum value of 0.44, and
a maximum value of 0.76. The group intestine has 5 observations with a mean of 16.20, a
standard deviation of 8.83, a minimum value of 7.20, and a maximum value of 26.60.
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Other Procedures
ANOVA is used to verify differences between groups. Five groups (ATCH-B, CHI,
DOM-1, DOM-2, and FRE are used for this analysis. The p value is below 0.0001, which is
below the significance level of 0.05. This concludes that at minimum, one group differs. The R2
value in the GLM is 0.774, which demonstrates that 77.4% of the response variables can be
explained or predicted by the groups. From the box plot distribution of results, it seems that
ATCH-B and FRE differ from CHI, DOM-1, and DOM-2. It is possible DOM-1 significantly
differs from all the other groups. Individual t tests should be performed to validate these
assumptions. Also, equality of variance tests and normality tests should be completed to draw
correct inferences.
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Chapter 7.5 – Cadmium Test Results and Statistics – Intestine

Sample Name
ATCH-B
CHI
DOM-1
DOM-2
FRE

Table 22 – Intestine
Result
Detection
(µg/kg)
Limit
7.20
3.74
<82.20
49.30
26.60
14.90
<33.60
20.20
<41.50
24.90
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Reference
Limit
6.24
82.20
24.80
33.60
41.50

Dilution
1
1
1
1
1

Chapter 7.6 – Cadmium Statistical Report
Fifty-three samples of tails were analyzed for cadmium. The sample mean, sample
standard deviation, the minimum, and the maximum values are reported in the table below.
Table 23 – Analysis Variable Results – Total Samples
N
Mean
Std Dev
Minimum
Maximum
53
4.05
3.35
0.44
10.10

The table below summarizes the key statistics for cadmium in the tails with intestine by
the site.
Table 24 – Analysis Variable Results – Tail with Intestine
Sample
Name
ATCH-B
CHI
DOM-1
DOM-2
FRE

N

Mean

Std Dev

Minimum

Maximum

12
10
10
10
11

1.41
7.34
4.15
7.64
0.59

2.559
0.990
1.980
1.340
0.110

0.49
5.90
0.62
5.56
0.44

9.50
9.15
6.30
10.10
0.76

The table below summarizes the key statistics for the intestine.

N
5

Table 25 – Analysis Variable Results – Intestine
Mean
Std Dev
Minimum
Maximum
16.20
8.83
7.20
26.60

Statistical Comparison of Tails and Intestines: There are 53 readings for the tails and only
five for the intestine. In the plots, the variable intestine is coded as Y for the cadmium in
intestines and as N for the cadmium in tails. The first figure summarizes the statistical
distribution for the two. Graphically, the fitted normal distribution does not fit for both tails and
intestines. The figure below also depicts boxplots for these two populations. The boxplot for tails
shows a long right tail and a long left tail for the intestine. This is studied further via generalized
linear modeling.
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Figure 6 – Distribution of Result – Tails and Intestines
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A QQ plot for the tails and intestines shows mild departure from the normality. The
sample size from tails is moderately large, and the central limit theorem will ensure the normality
requirement for the statistical tests provided below.
Figure 7 – Q-Q Plots of Result
Q-Q Plots of Result
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The comparisons of the means for the cadmium in the tails versus intestines is carried out
next using the t test. The mean cadmium in the tails is about 4.05 µg/kg, whereas it is 16.20 in
the intestine.
Table 26 – T Test
Intestine
Type
N
Y
Diff (1 – 2)

N

Mean

Std Dev

Std Err

Minimum

Maximum

53
5

4.05
16.20
-12.15

3.35
8.83
4.00

0.46
3.95
1.87

0.44
7.20

10.10
26.60
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The table below provides 95% confidence limits for the mean cadmium contents in the
tails, intestines, and the difference between the intestines and the tails. The table also provides
95% confidence limits for the standard deviations. For the mean differences, both pooled which
assumes equal variances for tails and intestines, and Satterthwaite are provided in the table
below. The confidence limits for the standard deviations are of the equal-tailed variety. Note that
the sample standard deviation for the cadmium in the tails is 3.35 µg/kg, whereas for intestines it
is 8.83 µg/kg. This difference in standard deviations (or variances) is tested via a folded f-test
and the test concludes that the variances are unequal with p value of 0.0003.

Type

Method

N
Y
Pooled
Diff (1 – 2)
Diff (1 – 2) Satterthwaite

Table 27 – 95% Confidence Limits
Mean
95% CL Mean
Std Dev
4.05
3.13
4.97
3.35
16.20
5.24
27.16
8.83
-12.15
-15.90
-8.40
4.00
-12.15
-23.07
-1.23

95% CL Std Dev
2.81
4.15
5.29
25.37
3.38
4.91

The tables below provide the p values for the difference in the mean cadmium contents
between tails and intestines under both equal and unequal variances. Assuming the variances are
equal the p value of the difference is highly significant (p value < 0.0001), whereas assuming
that the variances are unequal, the p value is 0.0365.

Method
Pooled
Satterthwaite

Method
Folded F

Table 28 – P values
Variances
DF
t Value
Equal
56.0000
-6.49
Unequal
4.1094
-3.06

Pr > |t|
<0.0001
0.0365

Table 29 – P-value – Equality of Variances
Num DF
Den DF
F Value
4
52
6.94

Pr > F
0.0003
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Statistical Comparison of Tails: The figure below shows the boxplots of cadmium contents in
the crayfish tails by site.
Distribution
of Result byofSAMPLENAME
Figure
8 – Distribution
Results – Tails
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A quick visual inspection shows that ATCH-B and FRE sites have the lowest levels of
cadmium in the tails, whereas DOM-2 is the highest. DOM-1 and CHI are a bit less in the
cadmium contents in the tails. Next, via a GLM, an unbalanced ANOVA model is fitted.
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First, we test the assumption of the equality of the variances by Levene’s test. Note that
the Levene’s Test does not reject the assumption of homogeneity of variance with a p value of
0.0721.
Table 30 – Levene’s Test for Homogeneity of Result Variance
ANOVA of Absolute Deviations from Group Means
Sum of
Mean
Source
DF
F Value
Pr > F
Squares
Square
4
13.6204
3.4051
2.30
0.0721
Sample Name
48
70.9991
1.4791
Error

Next, we report the results of the ANOVA test which assumes equality of the variances.

Source

DF

Model
Error
Corrected Total

4
48
52

Table 31 – ANOVA Test Result
Sum of
Mean Square
Squares
452.2500
113.0625
131.7807
2.7454
584.0308

F Value

Pr > F

41.18

<0.0001

The ANOVA test concludes that there is a statistically significant difference in the mean
cadmium in tails from the five sites with a p value of <0.0001.
Tukey's Studentized Range (HSD) Test (Post Hoc): The post hoc tests are designed for further
investigation into the situations when the f-test is significant and the researcher is interested in
which means are significantly different from each other. The post hoc test we used is Tukey’s
studentized range test, which corrects for multiple tests so that a correct Type I experiment error
rate is maintained even though multiple tests or comparisons are computed.
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The tables below summarize the Tukey’s test. Statistically significant differences at the
5% level are indicated below.
Table 32 – Turkey’s Studentized Range (HSD) Test
0.05000
Alpha
48.00000
Error Degrees of Freedom
2.74540
Error Mean Square
4.00812
Critical Value of Studentized Range
Table 33 – Turkey’s Studentized Range (HSD) Test
Comparisons significant at the 0.05 level are indicated by ***
Difference
Sample Name
Simultaneous 95%
Between
Comparison
Confidence Limits
Means
0.2950
-1.8051
2.3951
DOM-2 – CHI
3.4850
1.3849
5.5851
***
DOM-2 – DOM-1
6.2281
4.2174
8.2388
***
DOM-2 – ATCH-B
7.0433
4.9914
9.0951
***
DOM-2 – FRE
-0.2950
-2.3951
1.8051
CHI – DOM-2
3.1900
1.0899
5.2901
***
CHI – DOM-1
5.9331
3.9224
7.9438
***
CHI – ATCH-B
6.7483
4.6964
8.8001
***
CHI – FRE
-3.4850
-5.5851
-1.3849
***
DOM-1 – DOM-2
-3.1900
-5.2901
-1.0899
***
DOM-1 – CHI
2.7431
0.7324
4.7538
***
DOM-1 – ATCH-B
3.5583
1.5064
5.6101
***
DOM-1 – FRE
-6.2281
-8.2388
-4.2174
***
ATCH-B – DOM-2
-5.9331
-7.9438
-3.9224
***
ATCH-B – CHI
-2.7431
-4.7538
-0.7324
***
ATCH-B – DOM-1
0.8152
-1.1450
2.7754
ATCH-B – FRE
-7.0433
-9.0951
-4.9914
***
FRE – DOM-2
-6.7483
-8.8001
-4.6964
***
FRE – CHI
-3.5583
-5.6101
-1.5064
***
FRE – DOM-1
-0.8152
-2.7754
1.1450
FRE – ATCH-B

Summary and Limitations: The difference between tails and intestines is mildly statistically
significant. Due to small sample size for intestines in the CHI, DOM-1 and DOM-2, sites having
more cadmium in the tails, the overall difference between tails and intestines is mildly
statistically significant
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There is a strong statistically significant difference between the 5 sites. The cadmium
content FRE and ATCH-B is not statistically significant. Also, DOM-2 and CHI are not
significantly significant. The rest all are statistically different.
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Chapter 7.7 – Copper Test Results and Statistics – Tail with Intestine

Sample Name
ATCH-B-1
ATCH-B-2
ATCH-B-3
ATCH-B-4
ATCH-B-5
ATCH-B-6
ATCH-B-7
ATCH-B-8
ATCH-B-9
ATCH-B-10
ATCH Extra
ATCH Extra & 11 TS
CHI-1
CHI-2
CHI-3
CHI-4
CHI-5
CHI-6
CHI-7
CHI-8
CHI-9
CHI-10
DOM-1-1
DOM-1-2
DOM-1-3
DOM-1-4
DOM-1-5
DOM-1-6
DOM-1-7
DOM-1-8
DOM-1-9
DOM-1-10
DOM-2-1
DOM-2-2
DOM-2-3
DOM-2-4
DOM-2-5
DOM-2-6
DOM-2-7
DOM-2-8

Table 34 – Tail with Intestine
Result
Detection
Reference
(µg/kg)
Limit
Limit
286.00
1.730
2.89
435.00
1.300
2.17
467.00
1.110
1.84
580.00
1.260
2.11
371.00
1.120
1.86
598.00
1.500
2.49
396.00
0.976
1.63
463.00
1.590
2.66
598.00
1.460
2.43
435.00
1.110
1.85
365.00
1.900
3.17
252.00
1.610
2.69
461.00
14.600
24.30
540.00
14.000
23.30
573.00
15.700
26.20
254.00
16.300
27.20
633.00
12.100
20.10
361.00
13.400
22.30
365.00
18.300
30.50
203.00
14.800
24.70
312.00
15.800
26.40
512.00
11.800
19.70
536.00
1.230
2.05
<2.13
1.280
2.13
419.00
8.990
15.00
513.00
10.900
18.20
333.00
9.960
16.60
547.00
7.360
12.30
480.00
9.760
16.30
328.00
9.920
16.50
390.00
12.600
21.00
274.00
11.000
18.40
278.00
15.700
26.20
250.00
13.500
22.50
292.00
17.200
28.70
247.00
11.100
18.50
367.00
13.500
22.50
289.00
13.700
22.80
296.00
14.300
23.80
322.00
20.200
33.60
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Dilution
1
1
1
1
1
1
1
1
1
1
1
1
10
10
10
10
10
10
10
10
10
10
1
1
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

Sample Name
DOM-2-9
DOM-2-10
FRE-1
FRE-2
FRE-3
FRE-4
FRE-5
FRE-6
FRE-7
FRE-8
FRE-9
FRE-10
FRE-Extra

(Table 34 cont.)
Result
Detection
(µg/kg)
Limit
434
18.300
300
15.200
358
1.490
454
1.050
267
1.510
280
1.210
361
0.873
308
0.949
319
0.986
270
1.230
460
1.100
372
1.250
431
1.370
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Reference
Limit
30.50
25.30
2.49
1.75
2.52
2.02
1.45
1.58
1.64
2.05
1.84
2.09
2.28

Dilution
10
10
1
1
1
1
1
1
1
1
1
1
1

Chapter 7.8 – Copper Test Results and Statistics – Intestine

Sample Name
ATCH-B
CHI
DOM-1
DOM-2
FRE

Table 35 – Intestine
Result
Detection
(µg/kg)
Limit
695
49.30
1680
3.74
871
20.20
289
24.90
589
14.90
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Reference
Limit
82.20
6.240
33.60
41.50
24.80

Dilution
1
1
1
1
1

Chapter 7.9 – Zinc Test Results and Statistics – Tail with Intestine

Sample Name
ATCH-B-1
ATCH-B-2
ATCH-B-3
ATCH-B-4
ATCH-B-5
ATCH-B-6
ATCH-B-7
ATCH-B-8
ATCH-B-9
ATCH-B-10
ATCH Extra
ATCH Extra & 11 TS
CHI-1
CHI-2
CHI-3
CHI-4
CHI-5
CHI-6
CHI-7
CHI-8
CHI-9
CHI-10
DOM-1-1
DOM-1-2
DOM-1-3
DOM-1-4
DOM-1-5
DOM-1-6
DOM-1-7
DOM-1-8
DOM-1-9
DOM-1-10
DOM-2-1
DOM-2-2
DOM-2-3
DOM-2-4
DOM-2-5
DOM-2-6
DOM-2-7
DOM-2-8

Table 36 – Tail with Intestine
Result
Detection
Reference
(µg/kg)
Limit
Limit
7120
27.1
231
8630
203.0
1730
9590
173.0
1470
11300
198.0
1690
5680
175.0
1490
11800
234.0
1990
9370
153.0
1300
8800
250.0
2130
7440
229.0
1950
8410
174.0
1480
9810
297.0
2530
16100
253.0
2150
8770
228.0
1940
10700
219.0
1860
8050
246.0
2090
8400
256.0
2180
14200
189.0
1610
10400
209.0
1780
10700
287.0
2440
7540
232.0
1970
8820
248.0
2110
11600
185.0
1570
13200
192.0
1640
14000
200.0
1700
8520
141.0
1200
8970
171.0
1460
9890
156.0
1330
10300
115.0
982
9430
153.0
1300
8760
155.0
1320
11300
197.0
1680
8520
173.0
1470
8280
246.0
2090
8790
212.0
1800
8730
270.0
2300
9840
173.0
1480
7660
211.0
1800
7310
214.0
1820
8130
223.0
1900
8530
316.0
2690
114

Dilution
1
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10

Sample Name
DOM-2-9
DOM-2-10
FRE-1
FRE-2
FRE-3
FRE-4
FRE-5
FRE-6
FRE-7
FRE-8
FRE-9
FRE-10
FRE-Extra

(Table 36 cont.)
Result
Detection
(µg/kg)
Limit
7560
287
8430
238
10200
234
10300
164
10200
237
10900
190
11600
137
8810
148
9880
154
10400
192
10100
173
12400
196
11700
214
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Reference
Limit
2440
2020
1990
1400
2010
1610
1160
1260
1310
1640
1470
1670
1830

Dilution
10
10
10
10
10
10
10
10
10
10
10
10
10

Chapter 7.10 – Zinc Test Results and Statistics – Intestine

Sample Name
ATCH-B
CHI
DOM-1
DOM-2
FRE

Table 37 – Intestine
Result
Detection
(µg/kg)
Limit
3750
390.0
5910
316.0
<6580
772.0
4960
232.0
7710
58.6
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Reference
Limit
3320
2960
6580
1980
499

Dilution
1
1
1
1
1

Chapter 8 – Discussion
The results from the four man-made ponds vary greatly from the data taken at the
Atchafalaya Basin site. The mean sample data for the crawfish ponds DOM-1, DOM-2, and FRE
(Tables 10 and 11) show statistical parity. The CHI samples showed a much higher arsenic,
concentration compared to the Atchafalaya Basin samples, which contained the lowest levels
(Table 8). Research by Luckette and LSU A & M College showed a statistically higher
percentage of pancreatic cancer from cadmium in the CHI sample location as compared to the
other locales (Table 21). This could be the result of arsenic and cadmium concentrations in grain
fed animals (especially pork) and the amount of arsenic and cadmium-laden rice consumed there.
Research suggests that 1 in 16 cancer deaths are attributable to cadmium exposure and the
resultant pancreatic cancer in the CHI area (Luckett et al., 2012). The data represented in Tables
21 and 22 support this theory.
1.6 million tons of arsenic-laden fertilizers, pesticides, and insecticides have been used in
Louisiana agriculture since 1901, making rice products a major source of environmental arsenic.
It accumulates in plants and the effects are passed on to humans when ingested (Snyder &
Slaton, 2001). Research on rice products states that MMA and DMA metabolites produced after
rice is ingested may cause cancer in humans. Threshold levels of arsenic are created by continual
ingestion of rice products, possibly altering DNA which can lead to mutations in the human body
and cancer (Shen et al., 2007).
Water supplies are tested and monitored by municipalities and counties for MRLs by the
EPA. Regulating water sources mitigates exogenous arsenic. Accumulation increases threshold
levels thereby affecting DNA that may lead to cancer. (ATSDR, 2009) The natural production of
crayfish in the Atchafalaya Basin seems to be less influenced by contamination from agricultural
products and oil well leakages. Lower arsenic and cadmium concentration test results in the
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Atchafalaya Basin show, relative to the mean value of 84 µg/kg, a lesser segregated mean
percentage (Table 10). Levee protection from potentially harmful substances prevents
destruction of flora and fauna, and limited use of fertilizers, pesticides, and herbicides protect
indigenous plants and wildlife.
Effects from nearby sugar cane agriculture are of little consequence relative to arsenic
concentrations as shown in test results in the DOM-1 and DOM-2 pond sites (Table 8). There
was no indication of deleterious effects to animals in the tested areas.
Intestine samples showed a much higher concentration of arsenic as compared to tail
samples (Table 9). The concentrations on average were 6-7 times higher percentages in parts per
billion (ppb). The research would suggest removing the intestine after boiling before consuming
the crayfish to reduce the potentially harmful effects of inorganic arsenic (Table 9). It is unclear
whether ingestion of organic arsenic in crayfish contributes to a risk of cancer, and more research
is needed.
Copper is an essential nutrient for homeostasis in the human body. Food sources usually
supply the body with ample amounts. The RDA for copper is 0.9 mg/day, whereas the median
intake from a typical U.S. diet ranges from 1-1.6 mg/day. The safest highest intake of copper for
chronic exposure is 10 mg/day. Copper intake in the tested areas is substantially higher than
daily tolerable intake values. Ingesting 20-25 crayfish in one meal is enough to surpass the
tolerable intake level of 10,000 ppb. Copper concentrations are somewhat greater in the crayfish
intestine, but not so in all samples tested (Tables 34 and 35). The DOM-2 pond showed an
appreciable lower difference in the copper concentration, but more research is needed to quantify
better statistics. If the tails were consumed without the intestines, copper concentrations could be
reduced.

118

Zinc concentration results may also surpass the minimum or adequate levels for dietary
consumption. The upper allowable intake of zinc is 40 mg/day. The crayfish tails tested depict
higher concentrations than the UL and pose the risk of deleterious effects to humans or animals.
The research showed that the intestine zinc levels were lower compared to the other 3 metals
tested (Tables 36 and 37).
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Chapter 9 – Conclusion
The WHO has established .25 mg/kg as the average daily food and as much as 2.4 – 16.7
mg/kg in seafood. Water guidelines for oral ingestion by municipalities set by the EPA is 10
µg/L (WHO, 2001). Arsenic intake differs with foods ingested. Rice contains a higher level of
inorganic arsenic obtained from pesticides, herbicides, fungicides, and fertilizers used in the
growing process. Most foods would be contaminated with pesticides or herbicides to some
degree, unless grown with no application for eradication or control of insects and weeds. Cereals
and grains have a higher content of cadmium as well as tobacco, along with leafy vegetables
such as lettuce (Roman et al., 2010).
The research herein suggests the median content for arsenic in the ponds and Atchafalaya
Basin wild domain tested is 84 µg/k per tail sample, inclusive of the intestine. There is a higher
percentage of arsenic in the CHI samples tested in tail tissue, as compared to the other 3 manmade ponds, and a lower arsenic content in the Atchafalaya Basin samples. The research showed
the arsenic content in the Atchafalaya Basin crayfish at a lower concentration than all samples
tested as the result of little or no effect from pesticides, herbicides, and fungicides.
Research herein shows a much higher concentration of arsenic in the intestine, 6-7 times
higher, suggesting that one should not consume the intestine when eating crayfish. There is no
conclusive research that crayfish themselves cause disease. Based on these results, the possible
accumulation of arsenic in crayfish, depending incidence and amounts consumed annually could
be responsible for deleterious effects, such as DNA interruption and even cancer. Consuming the
tail and intestine is the basis for arsenic, cadmium, copper, and zinc concentrations possibly
surpassing the MRL guidelines as set by the ATSDR and other government agencies.
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Future research projects should also include eastern Louisiana as well as southeast Texas,
and central to southern Arkansas. This would provide a more pervasive statistical analysis of
heavy metal percentages from the three states that produce high volumes of crayfish for
consumption. Soil samples and water supplies would also be addressed in each venue, before
commencing with tail and intestine testing.
Differences in metal concentrations could possibly be traced back to the indigenous metal
nomenclature of the soil or usage of a product from a particular pesticide, herbicide, fungicide or
fertilizer. The testing of tail tissues with the intestine removed would also provide further
analysis of heavy metal contamination.
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